Document:

<PAGE>

                                                                   EXHIBIT 10.27

                              EMPLOYMENT AGREEMENT

         THIS EMPLOYMENT AGREEMENT (this "Agreement") is made and entered into
as of October 1, 2003 (the "Effective Date") by and between LUMINEX CORPORATION,
a Delaware corporation ("Luminex") and DAVID S. REITER ("Executive").

                                     RECITAL

         WHEREAS, Executive is to be employed as the Vice President, General
Counsel and Corporate Secretary of Luminex;

         WHEREAS, Luminex and Executive wish to document the terms of the
employment of Executive in such capacity; and

         WHEREAS, Executive has represented to Luminex and Luminex has relied on
Executive's representation that the execution of this Agreement by Executive,
and the provision of services by Executive to Luminex as contemplated in this
Agreement, will not conflict with, or cause Executive or any other person or
entity to be in breach of, (i) any other contract to which Executive is a party
or (ii) any duty which Executive may owe to any other person or entity.

                                    AGREEMENT

         NOW, THEREFORE, for good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, the parties agree as follows:

         1.       DUTIES.

                  1.1      Duties. During the term of this Agreement (including
all renewal periods, if any, the "Term"), Executive agrees to be employed by and
to serve Luminex as Vice President, General Counsel and Corporate Secretary and
Luminex agrees to employ and retain Executive in such capacity subject to the
provisions of this Agreement. Executive shall have such powers, authority and
duties, and shall render such services of executive and administrative
character, or act in such other capacity for Luminex, as the Chief Executive
Officer or the Board of Directors of Luminex (the "Board") shall from time to
time lawfully direct and Executive shall report directly to the Chief Executive
Officer of Luminex. Executive shall devote all of his business time, energy, and
skill to the business of Luminex; provided, however, that Executive shall be
permitted to continue his administrative and marketing responsibilities on
behalf of Phillips & Reiter, PLLC, but only to the extent such activities
neither (i) conflict with Executive's obligations set forth under this Agreement
nor (ii) detract from Executive's contribution to Luminex as a full-time
employee or Executive's responsibilities and duties as Vice President, General
Counsel and Corporate Secretary of Luminex. Luminex and Executive agree that, in
the event any dispute should arise between Luminex and Executive in respect of
the exception

<PAGE>

articulated in the immediately preceding sentence, the preceding sentence shall
be construed in the manner most favorable to Luminex.

                  1.2      Special Provisions Regarding Part Time Employment.
Notwithstanding anything to the contrary contained in Section 1.1 or elsewhere
in this Agreement, during the period (the "Part Time Period") commencing on the
Effective Date and ending on January 15, 2004, Executive shall be obligated to
work only four days each week.

         2.       TERM AND TERMINATION.

                  2.1      Term. Subject to Section 2.2, the term of employment
of Executive by Luminex shall be one (1) year commencing on the Effective Date
and shall thereafter automatically renew for successive additional one-year
terms unless either party provides the other with written notice of its intent
not to renew this Agreement at least sixty (60) days prior to the end of the
Term (unless terminated earlier pursuant to the provisions of this Agreement).

                  2.2      Termination of Employment.

                           2.2.1  Termination For Cause. "Termination For Cause"
shall mean the termination by Luminex of Executive's employment with Luminex as
the result of Executive's material fraud upon Luminex or Executive's continued
material breach of this Agreement after receipt of written notice from Luminex
specifying such breach and failure by Executive to cure such breach within
fifteen (15) days from receipt of such notice. Executive's inability to perform
his obligations under this Agreement despite his best efforts as a result of a
permanent or temporary disability (as evidenced by a written determination from
a physician chosen by Executive and reasonably acceptable to Luminex) shall not
result in a Termination For Cause. In the event that Executive fails to cure the
breach within the fifteen (15) day cure period, the termination shall be
effective as of the date that Luminex notifies Executive of his termination
following the expiration of the fifteen (15) day cure period. Upon any
Termination For Cause, Executive shall be paid the Accrued Obligations (defined
below) within three (3) business days following the effective date of
termination.

                           2.2.2  Termination Other Than For Cause. "Termination
Other Than For Cause" shall mean (i) termination by Luminex of Executive's
employment with Luminex for any reason other than Termination For Cause,
Termination by Reason of Death, Termination by Reason of Incapacity or
Termination Upon Expiration of Agreement or (ii) termination by Executive upon
constructive termination of Executive's employment with Luminex by reason of (A)
a reduction in Executive's Base Salary (defined below); (B) a reduction in
Executive's title from Vice President, General Counsel and Corporate Secretary
of Luminex (whether by reason of Executive's removal from any of such offices or
Luminex's failure to reappoint Executive to any of such offices); (C) a Material
Diminution (defined below); (D) a requirement that Executive change his
principal place of business to a location that is outside the Office Area
(defined below), or (E) Luminex's continued material breach of this Agreement
after receipt of written notice from Executive specifying such breach and
failure by Luminex to cure such breach within fifteen (15) days from receipt of
such notice. Termination Other Than For Cause

                                       -2-

<PAGE>

may be effected by Luminex at any time by providing Executive with written
notice of such termination. The termination shall be effective as of the date of
the notice or such later date as may be determined by Luminex. Executive may
also effect a Termination Other Than For Cause upon written notice to Luminex at
any time any of the conditions for constructive termination set forth in clause
(ii) above (including without limitation, if applicable, the expiration of the
cure period) have been met. Upon any Termination Other Than For Cause, Executive
shall be paid (i) within three (3) business days following the effective date of
termination the amount of the Accrued Obligations and (ii) all severance
compensation provided in Section 4.1. For purposes of this Agreement, "Material
Diminution" means a material diminution by Luminex of Executive's duties,
powers, authority, functions or responsibilities without Executive's consent,
such that Executive is left with such duties, powers, authority, functions and
responsibilities (when viewed in the aggregate) that are materially diminished
compared to both (i) those duties, powers, authority, functions and
responsibilities conferred upon Executive at the Effective Date and (ii) those
duties, powers, authority, functions and responsibilities that are most
typically conferred upon the employee general counsel of companies having both
(i) an employee general counsel and (ii) revenues comparable to Luminex (based
on the revenues of Luminex at the time of determination). Luminex and Executive
agree that in the event there is an ambiguity with respect to the interpretation
or application of the definition of "Material Diminution", such ambiguity shall
be resolved according to the reasonable interpretation of such definition most
favorable to Luminex. For purposes of this Agreement, "Office Area" means the
geographical area within a 40 mile radius of Luminex's current principal office
at 12212 Technology Blvd., Austin, Texas.

                           2.2.3  Actual Voluntary Termination. "Actual
Voluntary Termination" shall mean termination by Executive of Executive's
employment with Luminex for any reason other than Termination For Cause,
Termination Other Than For Cause, Termination by Reason of Death or Termination
by Reason of Incapacity. In the event of an Actual Voluntary Termination,
Executive shall be paid within three (3) business days following the effective
date of termination the amount of the Accrued Obligations.

                           2.2.4  Termination by Reason of Incapacity. If,
during the Term, Executive shall become Permanently Disabled (defined below),
Luminex may terminate Executive's employment with Luminex effective on the
earliest date permitted under applicable law, if any, and such termination shall
be deemed "Termination by Reason of Incapacity". Upon termination of employment
under this Section, Executive shall be paid (i) within three (3) business days
following the effective date of termination the amount of the Accrued
Obligations and (ii) all severance compensation provided in Section 4.2. As used
herein, Executive shall be deemed "Permanently Disabled" if Executive is (i)
collecting long-term disability payments under a long-term disability plan
established for the benefit of Luminex's employees or executives generally or a
reasonably similar plan or (ii) if, and only if, no such long-term disability
plan is in effect at the time of determination, a physician selected by Luminex
and reasonably acceptable to Executive makes a written determination that
Executive is unable to perform his obligations under this Agreement despite his
best efforts by reason of any medically determinable physical or mental
impairment that can be expected to result in death or that has lasted or can be
expected to last for a continuing period of not less than 12 months.

                                       -3-

<PAGE>

                           2.2.5  Termination by Reason of Death. In the event
of Executive's death during the Term, Executive's employment with Luminex shall
be deemed to have terminated as of the date on which his death occurs and the
estate of Executive shall be paid (i) within fifteen (15) days following the
effective date of termination the amount of the Accrued Obligations and (ii) all
severance compensation provided in Section 4.3.

                           2.2.6  Termination Upon Expiration of Agreement. In
the event that Luminex refuses for any reason to extend this Agreement by giving
written notice at least 60 days prior to the initial or any renewal period as
set forth in Section 2.1, Executive shall be paid (i) within three (3) business
days following the effective date of termination the amount of the Accrued
Obligations and (ii) all severance compensation provided in Section 4.4. In the
event that Executive refuses for any reason (except as otherwise provided
herein) to extend this Agreement by giving written notice at least 60 days prior
to the initial or any renewal period as set forth in Section 2.1, the
termination shall be deemed an Actual Voluntary Termination.

                           2.2.7  Termination of Relationship with Affiliated
Entities. Unless agreed by Luminex (or a subsidiary thereof) and Executive in a
separate written agreement (other than corporate minutes, resolutions, charter
documents, bylaws and partnership agreements), upon the termination of
Executive's employment with Luminex for any reason, Executive shall tender a
written resignation of any positions he may have with Luminex and any and all of
Luminex's direct and indirect subsidiaries.

                           2.2.8  Definition of Accrued Obligations. As used in
this Agreement, "Accrued Obligations" means all accrued but unpaid salary,
accrued but unpaid vacation, sick leave, and similar pay (all determined in
accordance with Luminex's policies then in effect), and any appropriate business
expenses incurred by Executive in connection with his duties hereunder, all to
the date of termination.

         3.      SALARY, BENEFITS AND BONUS COMPENSATION.

                  3.1      Base Salary. As payment for the services to be
rendered by Executive as provided in Section 1 and subject to the terms and
conditions of Section 2, Luminex agrees to pay to Executive a "Base Salary" at
the rate of $15,000 per month during the Part Time Period and thereafter at the
rate of $210,000 per annum (or such greater amount as may be determined from
time to time by the Board or the Compensation Committee thereof) payable in
accordance with the then-current payroll policies of Luminex.

                  3.2      Bonuses. Executive may be eligible to receive a bonus
each year (provided, however, that Executive shall not be eligible to receive a
bonus in respect of the year ended December 31, 2003) in an amount up to 50% (or
such higher percentage as may be determined from time to time by the Board or
the Compensation Committee thereof) of Executive's Base Salary during the Term
and any extensions hereof, with the actual amount of any such bonus to be
determined in the sole discretion of the Board. The Board is under no obligation
to declare, and Luminex is under no obligation to pay, any bonus to Executive
under the terms of this Agreement. In the event Executive and Luminex are
parties to a written

                                       -4-

<PAGE>

agreement or plan executed by both Luminex and Executive that governs bonus
arrangements, and the provisions thereof conflict with this Section 3.2, the
terms of such other written agreement or plan shall supersede this Section 3.2.

                  3.3      Change in Control. In the event that both (i) a
Change in Control (defined below) of Luminex occurs during the Term and (ii)
Executive's employment with Luminex (or, as applicable, its successor in
interest) terminates for any reason (including without limitation an Actual
Voluntary Termination by Executive) at any time within six (6) months following
the occurrence of the Change in Control of Luminex, in lieu of any Severance
Compensation then owed or that otherwise would be owed in the future to
Executive under Section 4 of this Agreement, Luminex (or its successor in
interest) shall pay Executive both the Accrued Obligations and a lump sum
payment (the "Change in Control Payment") in an aggregate amount equal to the
sum of (i) the Bonus Amount (defined below), plus (ii) an amount equal to
Executive's annual Base Salary (at the highest rate in effect during the period
beginning six months immediately prior to the effective date of the Change of
Control through the date of termination) within three (3) business days after
the termination of Executive's employment. In the interest of clarity, Luminex
and Executive agree that, upon the termination of Executive's employment at any
time within six (6) months following the occurrence of the Change in Control of
Luminex, the provisions of Sections 4.1, 4.2, 4.3, 4.4, and 4.6 shall
automatically be deemed null and void and shall not apply with respect to any
termination of Executive's employment (whether such termination is effected in
connection with the Change in Control of Luminex or at any time in the future
following the Change in Control of Luminex), and under no circumstances shall
Luminex ever be obligated to pay Executive both a Change in Control Payment and
Severance Compensation under Section 4. For purposes of this Agreement, a
"Change in Control" of Luminex shall be deemed to have occurred if, after the
date of this Agreement:

         (A) any "Person" (as such term is used in Sections 13(d) and 14(d) of
the Securities Exchange Act of 1934, as amended (the "Exchange Act")) (other
than an Approved Person (as defined below)) becomes the "Beneficial Owner" (as
defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of a
majority or more of the then outstanding Common Stock of Luminex ("Common
Stock") (such Person, an "Acquiring Person"); or

         (B) Luminex merges or consolidates with any other corporation or other
entity, in each case other than a merger or consolidation which results in the
voting securities of Luminex outstanding immediately prior thereto continuing to
represent (either by remaining outstanding or by being converted into voting
securities of the surviving entity) at least a majority of the combined voting
power of the voting securities of Luminex or such surviving entity outstanding
immediately after such merger or consolidation; or

         (C) Luminex sells or disposes of all or substantially all of Luminex's
assets in one transaction or a series of related transactions; or

         (D) Luminex files a periodic or current report or proxy statement with
the Securities and Exchange Commission (the "SEC") disclosing that a "change in
control" (as such term is used in Item 1 of Form 8-K promulgated by the SEC) of
Luminex has occurred; or

                                      -5-

<PAGE>

          (E) If, as a result of nominations made by a person or group other
than the Board of Directors of Luminex, individuals who prior to such
nominations constitute the Directors of Luminex cease for any reason to
constitute at least a majority thereof within the two year period following such
nominations.

         As used in this Agreement, "Approved Person" means (1) an employee
benefit plan of Luminex (or a trustee or other fiduciary holding securities for
such a plan), or (2) a corporation owned, directly or indirectly, by the
stockholders of Luminex in substantially the same proportions as their ownership
of stock of Luminex, or (3) a Person not less than a majority of whose voting
securities are Beneficially Owned by Luminex after giving effect to the
transaction.

         As used in this Agreement, "Bonus Amount" means the annual bonus (if
any) received or to be received by Executive under Section 3.2 in respect of the
then most recently completed calendar year, or if no determination concerning
bonuses has been made for the most recently completed calendar year, then the
annual bonus (if any) for the previous calendar year.

         Any options ("Options") granted (including without limitation Options
that may be granted in the future) and restricted stock ("Restricted Stock")
issued (including without limitation Restricted Stock that may be issued in the
future) to Executive pursuant to any incentive plan of Luminex shall immediately
vest upon a Change in Control. Luminex shall take no action to facilitate a
transaction involving a Change in Control, including without limitation
redemption of any rights issued pursuant to any rights agreement, unless it has
taken such action as may be necessary to ensure that Executive has the
opportunity to exercise all Options he may then hold, and obtain certificates
containing no restrictive legends in respect of any Restricted Stock he may then
hold, at a time and in a manner that shall give Executive the opportunity to
sell or exchange the securities of Luminex acquired upon exercise of his Options
and upon receipt of unrestricted certificates for shares of Common Stock in
respect of his Restricted Stock, if any (collectively, the "Acquired
Securities"), at the earliest time and in the most advantageous manner any
holder of the same class of securities as the Acquired Securities is able to
sell or exchange such securities in connection with such Change in Control.
Luminex acknowledges that its covenants in the preceding sentence (the
"Covenants") are reasonable and necessary in order to protect the legitimate
interests of Luminex in maintaining Executive as one of its employees and that
any violation of the Covenants by Luminex would result in irreparable injuries
to Executive, and Luminex therefore acknowledges that in the event of any
violation of the Covenants by Luminex or its directors, officers or employees,
or any of their respective agents, Executive shall be entitled to obtain from
any court of competent jurisdiction temporary, preliminary and permanent
injunctive relief in order to (i) obtain specific performance of the Covenants,
(ii) obtain specific performance of the exercise of his Options, delivery of
certificates containing no restrictive legends in respect of his Restricted
Stock and the sale or exchange of the Acquired Securities in the advantageous
manner contemplated above or (iii) prevent violation of the Covenants; provided
nothing in this Agreement shall be deemed to prejudice Executive's rights to
damages for violation of the Covenants. In the event that the terms of any
separate written agreement concerning Options granted or Restricted Stock issued
to Executive conflict with the terms of this paragraph, the terms of this
paragraph shall control.

                                      -6-

<PAGE>

                  3.4      Additional Benefits. During the Term, Executive shall
be entitled to the following fringe benefits:

                           3.4.1  Benefits and Vacation. Executive shall be
eligible to participate in such of Luminex's benefits and deferred compensation
plans as are now generally available or later made generally available to
executive officers of Luminex. A termination or expiration of this Agreement for
any reason or for no reason shall not affect any rights which Executive may have
pursuant to any agreement, policy, plan, program or arrangement of Luminex
providing Executive benefits (including under any stock option agreement or
bonus plan or agreement which may exist), which rights shall be governed by the
terms thereof. Executive shall be entitled to three (3) weeks paid vacation each
calendar year (prorated for partial years), except that Executive shall not be
entitled to any vacation during the Part Time Period. Unless approved in advance
by the Board or a committee thereof, accrued vacation not taken in any
applicable period shall not be carried forward or used in any subsequent period.

                           3.4.2  Reimbursement for Expenses.

                                  3.4.2.1  Incidental Expenses. Luminex shall
reimburse Executive for reasonable and properly documented out-of-pocket
business and/or entertainment expenses incurred by Executive in connection with
his duties under this Agreement. Any such expenses shall be submitted by
Executive to Luminex on a periodic basis and will be paid in accordance with
standard Luminex policies and procedures.

                                  3.4.2.2  Moving Expenses. In the event of the
relocation of Luminex's headquarters to a location that is outside the Office
Area and Executive elects to relocate, Luminex shall (i) reimburse Executive for
any reasonable, out-of-pocket and adequately documented moving expenses incurred
by Executive in connection with the transfer of his residence and (ii) pay to an
Executive an amount of cash reasonably calculated by Luminex to negate adverse
income tax consequences to Executive of the foregoing reimbursement.

         4.       SEVERANCE COMPENSATION.

                  4.1      Severance Compensation in the Event of a Termination
Other Than For Cause. In the event Executive's employment is terminated as a
result of a Termination Other Than for Cause, Executive shall be paid (subject
to Section 4.6) the Severance Compensation (defined below).

                  4.2      Severance Compensation for Termination by Reason of
Incapacity. In the event Executive's employment is terminated as a result of a
Termination by Reason of Incapacity, Executive shall be paid (subject to Section
4.6) the difference of (i) the Severance Compensation less (ii) any payment or
payments received by Executive during the twelve (12) month period from the time
of termination under any long-term disability plan in effect that provides
benefits to Executive.

                                      -7-

<PAGE>

                  4.3      Severance Compensation for Termination by Reason of
Death. In the event Executive's employment is terminated as a result of
Executive's death, the estate of Executive shall be paid the Severance
Compensation.

                  4.4      Severance Compensation In the Event Of A Failure Of
Luminex To Renew This Agreement. In the event Luminex fails or otherwise refuses
for any reason to extend this Agreement beyond the Term and any extensions
thereof, Executive shall be paid (subject to Section 4.6) the Severance
Compensation.

                  4.5      No Severance Compensation Upon Other Termination. In
the event of an Actual Voluntary Termination or Termination For Cause, Executive
shall not be paid any severance compensation.

                  4.6      Conditions to Payment; Sole Remedy. Executive shall
not be entitled to receive any compensation or other payment pursuant to
Sections 4.1, 4.2 or 4.4 unless Executive shall have executed and delivered to
Luminex a release substantially in the form attached hereto as Exhibit "A" and,
provided Luminex has also signed such release within two (2) business days of
execution and delivery by Executive, all revocation and waiting periods
applicable to such release have expired (if Luminex fails to sign such release,
then such revocation and waiting periods shall not apply). In addition, in the
event that Executive breaches any of the restrictive covenants set forth in
Article 5 at any time, Luminex shall be entitled to discontinue any compensation
or other payments pursuant to Sections 4.1, 4.2 or 4.4 (provided, however, that
if it is finally determined by a court of competent jurisdiction or an
arbitrator that Luminex asserted in bad faith that Executive breached any of the
restrictive covenants set forth in Article 5, the payments of the Severance
Compensation shall be extended for two months for each calendar month that
payments were delayed. The compensation to be paid to Executive pursuant to
Sections 4.1, 4.2, 4.3 or 4.4 shall represent the sole and exclusive remedy of
Executive in connection with the termination of his employment and this
Agreement upon a Termination Other Than for Cause, a Termination by Reason of
Incapacity, a termination in connection with Executive's death, or a refusal by
Luminex to extend this Agreement beyond the Term and any extensions thereof.

                  4.7      Definition of Severance Compensation. As used in this
Agreement, "Severance Compensation" means an amount equal to the sum of (i) the
Bonus Amount plus (ii) an amount equal to Executive's annual Base Salary (at the
highest rate in effect for the six month period immediately prior to the date of
termination), paid in semi-monthly installments for a period of twelve (12)
months from the date of termination. In addition, as part of the Severance
Compensation, Luminex also shall pay (until the earlier of (A) the first annual
anniversary of the termination of this Agreement or (B) the date that Executive
is eligible to be covered under a comparable or more favorable health plan of
another Person) (i) COBRA payments in respect of the continuation of health
benefits for Executive, his spouse and his children and (ii) payments to fund
dental coverage for Executive, his spouse and his children comparable to the
dental coverage that they would have received if Executive had continued as an
employee of Luminex.

                                      -8-

<PAGE>

         5.       PROTECTION OF LUMINEX.

                  5.1      Non-Competition. Ancillary to the otherwise
enforceable agreements set forth in this Agreement, Executive agrees that during
Executive's employment with Luminex and for a period of one year following
termination of employment, whether such termination occurs at the insistence of
Executive or Luminex for any reason, Executive shall not compete directly or
indirectly in any way with the business of Luminex anywhere in the world where
Luminex conducted business during the Term. For purposes of this Agreement,
"compete directly or indirectly in any way with the business of Luminex" means
to become an employee, consultant, advisor, manager, member, director of or
beneficially own more than three percent of any individual, company or entity
that competes with Luminex in the Core Business (defined below) at the time of
determination. Executive agrees that the assertion or existence of any claim by
Executive against Luminex shall not be a defense to the enforcement of this
paragraph by injunction or otherwise. As used in this Agreement, "Core Business"
means the development, manufacturing and/or marketing of biological testing
technologies with applications in the life-sciences industry.

                  5.2      Nonsolicitation. Ancillary to the otherwise
enforceable agreements set forth in this Agreement, Executive agrees that, for a
period of one (1) year subsequent to the termination of Executive's employment
with Luminex, whether such termination occurs at the insistence of Executive or
Luminex for any reason, Executive shall not recruit, hire, or attempt to recruit
or hire, directly or by assisting others, any other employees of Luminex, nor
shall Executive contact or communicate with any other employees of Luminex for
the purpose of inducing other employees to terminate their employment with
Luminex. For purposes of this covenant, "other employees of Luminex" shall refer
to employees who are still actively employed by, or doing business with, Luminex
or a subsidiary of Luminex at the time of the attempted recruiting or hiring.

                  5.3      Remedies. Due to the irreparable and continuing
nature of the injury which would result from a breach of the covenants described
in Sections 5.1 and 5.2, Executive agrees that Luminex may, in addition to any
remedy which Luminex may have at law or in equity, apply to any court of
competent jurisdiction for the entry of an immediate order to restrain or enjoin
the breach of this covenant and to otherwise specifically enforce the provisions
of the covenants set forth in Sections 5.1 and 5.2.

                  5.4      Acknowledgment. Executive acknowledges and agrees
that the restrictions set forth above are ancillary to an otherwise enforceable
agreement and supported by independent valuable consideration as required by

TEX. BUS. & COMM. CODE ANN. Section 15.50. Executive further acknowledges and
agrees that the limitations as to time, geographical area, and scope of activity
to be restrained by Sections 5.1 and 5.2 are reasonable and acceptable to
Executive, and do not impose any greater restraint than is reasonably necessary
to protect the goodwill and other business interests of Luminex.

                  5.5      Reformation and Severance. If a judicial
determination is made that any of the provisions of the above restriction
constitutes an unreasonable or otherwise unenforceable

                                      -9-

<PAGE>

restriction against Executive, it shall be rendered void only to the extent that
such judicial determination finds such provisions to be unreasonable or
otherwise unenforceable. In this regard, the parties hereby agree that any
judicial authority construing this Agreement shall be empowered to sever any
portion of the prohibited business activity from the coverage of this
restriction and to apply the restriction to the remaining portion of the
business activities not so severed by such judicial authority. Moreover,
notwithstanding the fact that any provisions of this restriction are determined
by a court not to be specifically enforceable through injunctive relief, Luminex
shall nevertheless be entitled to seek to recover monetary damages as a result
of the breach of any provision which is not reformed by a court. The time period
during which the restrictions shall apply shall be tolled and suspended as to
Executive for a period equal to the aggregate quantity of time during which
Executive violates such prohibitions in any respect.

                  5.6      Confidential Information and Trade Secrets. As used
herein, "Confidential Information" means any data or information that is
important, competitively sensitive, and not generally known by the public or
persons involved in the biological testing or life sciences industries,
including, but not limited to, Luminex's business plans, Prospective Customers,
training manuals, proprietary software, product development plans, bidding and
pricing procedures, market plans and strategies, projections, internal
performance statistics, financial data, confidential personnel information
concerning employees of Luminex, operational or administrative plans, policy
manuals, and terms and conditions of contracts and agreements. The term
"Confidential Information" shall not apply to information which is (i) already
in Executive's possession (unless such information was obtained by Executive
from Luminex in the course of Executive's employment by Luminex); (ii) received
by Executive from a third party with, to Executive's knowledge, no restriction
on disclosure or (iii) required to be disclosed by any applicable law or by an
order of a court of competent jurisdiction.

         Executive recognizes and acknowledges that the Confidential Information
constitutes valuable, special and unique assets of Luminex and its affiliates.
Except as required to perform Executive's duties as an Executive of Luminex,
until such time as they cease to be Confidential Information through no act of
Executive in violation of this Agreement, Executive will not use or disclose any
Confidential Information of Luminex. Upon the request of Luminex and, in any
event, upon the termination of this Agreement for any reason, Executive will
surrender to Luminex (i) all memoranda, notes, records, drawings, manuals or
other documents pertaining to Luminex's business including all copies and/or
reproductions thereof and (ii) all materials involving any Confidential
Information of Luminex.

                  5.7      Preservation of Luminex Property. Executive
acknowledges that from time to time in the course of employment with Luminex,
Executive has had the opportunity to inspect and use certain property of
Luminex, both tangible and intangible, including but not limited to files,
records, documents, drawings, specifications, lists, equipment, graphics,
designs, and similar items relating to the business of Luminex. Executive
acknowledges and agrees that all such property, including but not limited to any
and all copies thereof, whether prepared by Executive or otherwise in the
possession of Executive, are and shall remain the exclusive property of Luminex,
that Executive shall have no right or proprietary interest in such property

                                      -10-

<PAGE>

and that Executive will safeguard and return to Luminex all such property upon
the earlier of (i) Luminex's request and (ii) the termination of Executive's
employment with Luminex.

                  5.8      Assignment of Inventions to Luminex. All computer
software, compilations, programs, improvements, inventions, notes, copyrightable
works, and opportunities for additional Luminex business, made, fixed,
conceived, or acquired by Executive during the Term are exclusively owned by
Luminex, are Luminex's works for hire, and fully assigned to Luminex including
without limitation all rights to renewals, extensions, causes of action,
reproduce, prepare derivative works, distribute, display, perform, transfer,
make, use and sell and may never be copied, used, or disclosed without Luminex's
express written consent. Executive will sign on request any documents affirming
the same for any particular item.

                  5.9      Notice to Subsequent Employers. Executive agrees
that, prior to commencing any new employment in the Core Business within twelve
months after the termination of this Agreement, Executive will furnish the new
employer with a copy of this Agreement. Executive also agrees that Luminex may
advise any new or prospective employer of the existence and terms of this
Agreement and furnish the employer with a copy of this Agreement.

         6.      DISCLOSURE OF INVESTMENTS. Commencing upon Executive's
execution of this Agreement and at all times during the Term, Executive shall
keep the Board informed in writing of the nature and extent of Executive's
investments, stock holdings, or retention as a director, advisor or any similar
interest in any business or enterprise involved in the Core Business other than
Luminex; provided, however, that Executive shall not be required to disclose any
such investments or stock holdings that constitute less than 1% of such entity's
total obligations or total voting power.

         7.       ARBITRATION.

                  7.1      Exclusive Remedy. Arbitration shall be the sole and
exclusive remedy for resolving any claim or dispute which cannot be mutually
resolved between the parties to this Agreement with the exception of disputes
arising out of Executive's obligations under Article 5 or disputes arising out
of Luminex's obligations under the last paragraph of Section 3.3, which are not
subject to this arbitration provision; provided however, that the parties hereto
agree that they may bring action in any court of competent jurisdiction to
enforce any award granted pursuant to arbitration or to otherwise enforce this
Article 7. This includes, but is not limited to, termination, interpretation or
application of this Agreement or any other agreement or policy of Luminex, any
claim of violation of law relating to the employment relationship, including,
without limitation, any claim of employment discrimination or sexual harassment,
or harassment based on any other prohibited basis, or any claim by Luminex
against Executive. This Agreement is a waiver of the right to trial by a jury or
court.

                  7.2      Limitations. The request for arbitration must be made
within one (1) year from the date of the occurrence giving rise to the dispute
or claim; or, in the event of a statutory claim, the time set forth by statute.

                                      -11-

<PAGE>

                  7.3      Rules and Procedures. The arbitration will be
conducted under the rules and procedures for arbitration of employment disputes
of the American Arbitration Association. The arbitration shall take place in
Austin, Texas unless the parties mutually agree to another location.

                  7.4      Arbitrator's Authority. Upon finding that a claim is
meritorious or in favor of one of the parties to the dispute, the arbitrator or
arbitrators shall have the authority to order legal and equitable remedies
appropriate as permitted by law.

                  7.5      Expenses. Costs of obtaining and paying the arbiter
and the costs associated with conducting the arbitration, including obtaining a
facility to be used during the arbitration, shall be paid by Luminex. Other
costs of the arbitration or any litigation associated with any dispute arising
under or in connection with this Agreement including, without limitation,
reasonable attorneys' and experts' fees and expenses of Luminex and the
Executive shall be borne by the party incurring such expense unless the arbiter
or court of law, as the case may be, awards costs to one of the parties.

         8.       MISCELLANEOUS.

                  8.1      Waiver. The waiver of the breach of any provision of
this Agreement shall not operate or be construed as a waiver of any subsequent
breach of the same or other provision hereof.

                  8.2      Entire Agreement; Modifications. Except as otherwise
provided herein, this Agreement represents the sole, entire, and complete
understanding among the parties with respect to the subject matter hereof, and
this Agreement supersedes any and all prior understandings, agreements, plans
and negotiations, whether written or oral, with respect to the subject matter
hereof, including without limitation any understandings, agreements or
obligations respecting any past or future compensation, bonuses, reimbursements
or other payments to Executive from Luminex. All modifications to the Agreement
must be in writing and signed by both Executive and Luminex.

                  8.3      Notices. All notices and other communications under
this Agreement shall be in writing and shall be given by facsimile or first
class mail, certified or registered with return receipt requested, and shall be
deemed to have been duly given three business days after mailing or one business
day after transmission of a facsimile (with confirmation of receipt) to the
respective persons named below:

                  If to Luminex:                     Luminex Corporation.
                                                     12212 Technology Blvd.
                                                     Austin, Texas 78727
                                                     Fax: (512) 219-5195
                                                     Attn: President

                                      -12-

<PAGE>

                  With a copy to                     Jackson Walker L.L.P.
                                                     901 Main Street, Suite 6000
                                                     Dallas, Texas 75202
                                                     Fax: (214) 953-5822
                                                     Attn: Michael E. Taten

                  If to Executive:                   David S. Reiter
                                                     9413 Savannah Ridge Drive
                                                     Austin, Texas 78726

Any party may change such party's address for notices by notice duly given
pursuant to this Section 8.3.

                  8.4      Headings. The Section headings herein are intended
for reference and shall not by themselves determine the construction or
interpretation of this Agreement.

                  8.5      Governing Law; Venue. This Agreement shall be
governed by and construed in accordance with the laws of the State of Texas.
Subject in all respects to Section 7 generally and Section 7.3 in particular,
any dispute arising out of or relating to this Agreement may be brought in a
court of competent jurisdiction located in Austin, Texas, and both of the
parties to this Agreement irrevocably submit to the exclusive jurisdiction of
such courts in any such dispute, waives any objection it may now or hereafter
have to venue or to convenience of forum, agrees that all claims in respect of
the dispute shall be heard and determined only in any such court, and agrees not
to bring any dispute arising out of or relating to this Agreement in any other
court. The parties agree that either or both of them may file a copy of this
paragraph with any court as written evidence of the knowing, voluntary and
bargained agreement among the parties irrevocably to waive any objections to
venue or to convenience of forum. Process in any dispute may be served on any
party anywhere in the world.

                  8.6      Severability. Should any court of competent
jurisdiction determine that any provision of this Agreement is illegal or
unenforceable to any extent, such provision shall be enforced to the extent
permissible and all other provisions of this Agreement shall continue to be
enforceable to the extent possible.

                  8.7      Counterparts. This Agreement may be executed in one
or more counterparts, all of which taken together shall constitute one and the
same Agreement.

                  8.8      Assignment. Neither this Agreement nor any duties or
obligations hereunder may be assigned by either party without the other party's
prior written consent; provided, however, that Luminex may assign this Agreement
to either (i) a wholly-owned subsidiary of Luminex (provided, however, that such
assignment shall not relieve Luminex of its obligations hereunder) or (ii) a
Person acquiring substantially all of Luminex's assets if such acquisition would
constitute a Change in Control.

                                      -13-

<PAGE>

                  8.9      Withholding. All compensation and benefits payable to
Executive hereunder shall be reduced by all federal, state, local and other
withholdings and similar taxes and payments required by applicable law.

                                      -14-

<PAGE>

         IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the day and year first above written.

                                      LUMINEX CORPORATION

                                      By: /s/ Thomas W. Erickson
                                          -------------------------------------

                                      EXECUTIVE

                                               /s/ David S. Reiter
                                      -----------------------------------------
                                                 David S. Reiter

                                      -15-

<PAGE>

                                   EXHIBIT "A"

                            GENERAL RELEASE AGREEMENT

         THIS GENERAL RELEASE AGREEMENT (this "Agreement") dated as of the day
of , _____________ __________, _______________ [FILL IN EFFECTIVE DATE OF
TERMINATION PURSUANT TO THE EMPLOYMENT AGREEMENT] (the "Effective Date"), is by
and between David S. Reiter ("Executive") and Luminex Corporation ("Luminex").

         WHEREAS, Executive's employment with Luminex has terminated pursuant to
that certain Employment Agreement dated as of October 1, 2003 (the "Employment
Agreement");

         NOW, THEREFORE, in consideration of the foregoing premises and other
good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto hereby agree as follows:

         1.      Termination of Employment. Executive and Luminex hereby agree
that Executive's employment with Luminex has terminated pursuant to Section
_____ [FILL IN APPLICABLE SECTION] of the Employment Agreement effective as of
the Effective Date. To the extent he continues to hold any such positions or
directorships, Executive hereby resigns all positions and directorships he holds
with Luminex and any and all of Luminex's subsidiaries and affiliates.

         2.      Release by Executive. Executive, on his own behalf and on
behalf of the Executive Released Parties (defined below), hereby irrevocably and
unconditionally releases and forever discharges Luminex, its respective
subsidiaries and other affiliated and their respective agents, employees,
representatives, officers, directors, stockholders, trustees and attorneys, past
and present, and the heirs, successors and assigns of all of the foregoing
(collectively, the "Released Parties") from any and all debts, liabilities,
claims, demands, actions or causes of action, suits, judgments or controversies
of any kind whatsoever (except as set forth below) arising from Executive's
relationship (including without limitation as a stockholder) to, employment with
or service as an employee, officer, director, or manager of Luminex or its
subsidiaries and affiliates (collectively, the "Claims") against the Released
Parties, that now exist or that may arise in the future out of any matter,
transaction or event occurring prior to or on the Effective Date, including
without limitation, any claims of breach of contract or for severance or other
termination pay (except as set forth in Section 4 below), or claims of
harassment or discrimination (for example, on the basis of age, sex, race,
handicap, disability, religion, color or national origin) under any federal,
state or local law, rule or regulation, including, but not limited to the Age
Discrimination in Employment Act of 1967, 29 U.S.C. Section 621, et seq. Except
as set forth below, Executive further agrees not to file or bring any claim,
suit, civil action, complaint, arbitration or administrative action (any of the
foregoing, an "Action") in any city, state or federal court or agency or
arbitration tribunal with respect to any Claim against any of the Released
Parties or (except as may be required by law) assist any other person or entity
with any Action against any of the Released Parties. Notwithstanding anything to
the contrary contained

                                       1

<PAGE>

in this Agreement, Executive does not release any of the Released Parties and
shall not be prohibited from filing or bringing an Action with respect to any
right Executive otherwise may have now or in the future to (i) receive
distributions or dividends made in respect of Luminex's capital stock or (ii) be
indemnified by Luminex under the Certificate of Incorporation or Bylaws of
Luminex (as the same are currently in effect), any resolution adopted by the
Board of Directors of Luminex, or any other separate written agreement or
instrument requiring Luminex to indemnify Executive or (iii) receive workers'
compensation claims or (iv) receive Accrued Obligations (as such term is defined
in the Employment Agreement) or (v) receive Severance Compensation (as such term
is defined in the Employment Agreement) or (vi) stock, options, and other
equity-based compensation that vested prior to the Effective Date or that vests
subsequent to the Effective Date pursuant to the Employment Agreement or an
applicable Luminex long-term incentive plan (which stock, options or other
equity-based compensation shall be governed by the terms and provisions of the
applicable written agreement(s) or instrument(s) and/or the applicable Luminex
incentive plan) or (vii) vested benefits payable under retirement and other
employee benefit plans covering Executive (which benefits shall be governed by
the terms and provisions of the applicable plan).

         3.       Release by Luminex. Luminex, on its own behalf and on behalf
of the Released Parties, hereby irrevocably and unconditionally releases and
forever discharges Executive and his heirs, successors and assigns
(collectively, the "Executive Released Parties") from any and all Claims against
the Executive Released Parties, that now exist or that may arise in the future.
Except as set forth below, Luminex further agrees not to file or bring any
Action in any city, state or federal court or agency or arbitration tribunal
with respect to any Claim against any of the Executive Released Parties or
(except as may be required by law) assist any other person or entity with any
Action against any of the Executive Released Parties. Notwithstanding anything
to the contrary contained in this Agreement, Luminex does not release any of the
Executive Released Parties and shall not be prohibited from filing or bringing
an Action with respect to (i) a breach by Executive after the Effective Date of
any of Executive's obligations under the Employment Agreement that by their
terms survive termination of the Employment Agreement, including without
limitation the provisions of Article 5 of the Employment Agreement, or (ii) in
connection with any claim for indemnification by Executive, any obligation or
burden of proof applicable to Executive that is a condition to Executive's right
to be indemnified by Luminex under the Certificate of Incorporation or Bylaws of
Luminex (as the same are currently in effect), any resolution adopted by the
Board of Directors of Luminex, or any other separate written agreement or
instrument requiring Luminex to indemnify Executive or (iii) any Claims that
arise out of any criminal or fraudulent activity, willful misconduct or gross
negligence of Executive.

         4.       Severance Compensation. In consideration of Executive's
execution of this Agreement, Executive shall be entitled to receive from Luminex
the Severance Compensation under one of Section 4.1, 4.2 or 4.4 in the
Employment Agreement. Executive acknowledges that no other promise or agreements
of any kind have been made to Executive or with Executive by any person or
entity whatsoever to cause Executive to sign this Agreement. Executive further
acknowledges and agrees that the Severance Compensation, together with any other
payments or benefits that may be due under the terms of the Employment
Agreement, shall constitute full accord and satisfaction of all obligations,
including without limitation any and all severance

                                      2

<PAGE>

obligations, in connection with Executive's employment. Executive would not be
entitled to receive the Severance Compensation but for Executive's execution of
this Agreement.

         5.       Disclaimer of Liability. Executive acknowledges that this
Agreement shall not in any way be construed as an admission by Executive or any
of the Released Parties of any wrongful or illegal act against the other or any
other person, and that Executive and the Released Parties expressly disclaim any
liability of any nature whatsoever arising from or related to the subject of
this Agreement.

         6. COMPETENCY. EXECUTIVE ACKNOWLEDGES THE FOLLOWING:

                  a.       THAT HE FULLY COMPREHENDS AND UNDERSTANDS ALL OF THE
                           TERMS OF THIS AGREEMENT AND THEIR LEGAL EFFECTS;

                  b.       THAT HE IS COMPETENT TO EXECUTE THIS AGREEMENT;

                  c.       THAT IT IS EXECUTED KNOWINGLY AND VOLUNTARILY AND
                           WITHOUT RELIANCE UPON ANY STATEMENT OR REPRESENTATION
                           OF ANY RELEASED PARTY OR ITS REPRESENTATIVES;

                  d.       THAT HE HAS BEEN ADVISED IN WRITING TO CONSULT WITH
                           AN ATTORNEY BEFORE EXECUTING THIS AGREEMENT AND THAT
                           HE HAS HAD THE OPPORTUNITY TO CONSULT WITH AN
                           ATTORNEY OF HIS CHOICE REGARDING THIS AGREEMENT;

                  e.       THAT EXECUTIVE DOES NOT WAIVE RIGHTS OR CLAIMS THAT
                           MAY ARISE AFTER THE DATE THIS AGREEMENT IS EXECUTED;

                  f.       THAT EXECUTIVE WAIVES RIGHTS OR CLAIMS UNDER THIS
                           AGREEMENT ONLY IN EXCHANGE FOR CONSIDERATION IN
                           ADDITION TO ANYTHING OF VALUE TO WHICH THE EXECUTIVE
                           WAS ALREADY ENTITLED;

                  g.       [THAT HE HAS BEEN PROVIDED THE MATERIALS REGARDING
                           THE CLASS, UNIT, OR GROUP OF INDIVIDUALS ELIGIBLE FOR
                           THIS COMPENSATION AND THE TIME LIMITS APPLICABLE TO
                           SUCH PROGRAM;] [This clause to be included if
                           required by or advisable under applicable law.]

                  h.       [THAT HE HAS BEEN PROVIDED THE JOB TITLES AND AGES OF
                           ALL INDIVIDUALS ELIGIBLE OR SELECTED FOR THE PROGRAM
                           AND THE AGES OF ALL INDIVIDUALS IN THE SAME JOB
                           CLASSIFICATION OR ORGANIZATIONAL UNIT WHO ARE NOT
                           ELIGIBLE OR SELECTED FOR THE PROGRAM;] [This clause
                           to be included if required by or advisable under
                           applicable law.]

                                        3

<PAGE>

                  i.       THAT HE HAS HAD A PERIOD OF AT LEAST 21 DAYS [or 45
                           days, if required by or advisable under applicable
                           law] WITHIN WHICH TO CONSIDER THIS AGREEMENT;

                  j.       THAT FOR A PERIOD OF SEVEN DAYS FOLLOWING THE
                           EXECUTION OF THIS AGREEMENT, EXECUTIVE MAY REVOKE
                           THIS AGREEMENT AND IT SHALL NOT BECOME EFFECTIVE OR
                           ENFORCEABLE UNTIL THE SEVEN-DAY PERIOD HAS EXPIRED OR
                           SUCH LATER DATE AS PROVIDED FOR HEREIN.

         7.       Parties in Interest. This Agreement is for the benefit of the
Released Parties and shall be binding upon Executive and his representatives and
heirs.

         8.       Governing Law. This Agreement and the rights and obligations
of Executive hereunder shall be governed by and construed and enforced in
accordance with the substantive laws of the State of Texas.

         9.       Amendment. This Agreement may not be clarified, modified,
changed or amended except in writing and signed by Executive and Luminex or a
successor-in-interest of Luminex.

         10.      Non-disparagement. Executive agrees that he will refrain from
speaking ill of or making any disparaging comment about Luminex or Luminex's
management, other employees or contractors, following the termination of his
employment except as may be necessary or advisable, in the reasonable judgment
of Executive, to enforce his rights under this Agreement, enforce claims arising
after the Effective Date and not released in this Agreement, or defend a legal
action brought against Executive by any of the Released Party. Luminex agrees
that it will refrain from speaking ill of or making any disparaging comment
about Executive following the termination of his employment except as may be
necessary or advisable, in the reasonable judgment of Luminex, to (i) to enforce
its rights under the Employment Agreement or this Agreement not released in this
Agreement or (ii) defend a legal action brought against any of the Released
Parties by Executive or (iii) comply with applicable securities laws or protect
Luminex from potential liability.

         11.      Enforcement of Laws. Nothing in this Agreement affects the
rights and responsibilities of the Equal Employment Opportunity Commission (the
"Commission") to enforce the anti-discrimination laws, and this waiver does not
affect Executive's right to file a charge or participate in an investigation or
proceeding with the Commission. However, Executive waives any rights or claims,
known or unknown, to participate in any recovery under any proceeding or
investigation by the Commission or any state or local commission concerned with
the enforcement of anti-discrimination laws

         12.      Severability. If any provision of this Agreement is held to be
illegal, invalid or unenforceable under present or future laws, such provision
shall be fully severable and this Agreement shall be construed and enforced as
if such illegal, invalid or unenforceable provision never comprised a part
hereof; and the remaining provisions hereof shall remain in full force and

                                       4

<PAGE>

effect and shall not be affected by the illegal, invalid or unenforceable
provision, and there shall be added automatically as part of this Agreement a
provision as similar in its terms to such illegal, invalid or unenforceable
provision as may be possible and be legal, valid and enforceable.

                                       5

<PAGE>

         IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the day and year first above written.

                                            LUMINEX CORPORATION

                                            By:
                                                --------------------------------

                                            EXECUTIVE

                                            ------------------------------------

                                            David S. Reiter, individually

                                       6EX-4.9 CONVERTIBLE REDEEMABLE EXCHANGEABLE

 

EXHIBIT 4.9

WEBMD CORPORATION

CONVERTIBLE REDEEMABLE EXCHANGEABLE

PREFERRED STOCK

PURCHASE AGREEMENT

MARCH 4, 2004

 

 

PURCHASE AGREEMENT

March 4, 2004

CalPERs/PCG Corporate Partners, LLC

c/o Pacific Corporate Group LLC

1200 Prospect Street, Suite 200

La Jolla, CA 92037
        as
Investor

Dear Sirs and Mesdames:

          WebMD Corporation, a Delaware corporation (the “Company”), has duly
authorized the sale and issuance to the investor named in Schedule A hereto
(the “Investor”) up to 10,000 shares of its Convertible Redeemable Exchangeable
Preferred Stock, par value $0.0001 per share (the “Preferred Stock”), having
the rights, restrictions, privileges and preferences set forth in the
Certificate of Designations in the form attached hereto as Exhibit A (the
“Certificate”) filed concurrently with the Secretary of State of the State of
Delaware.

          The shares of Preferred Stock will be convertible in accordance with their
terms and the terms of the Certificate into shares of the common stock, par
value $0.0001 per share (the “Common Stock”), of the Company, and the Company
has reserved a sufficient number of its authorized but unissued shares of
Common Stock in order to satisfy the rights upon conversion of the shares of
Preferred Stock. The shares of Preferred Stock also will be exchangeable for
the Company’s 10% Subordinated Notes due 2010 (the “Subordinated Notes”), which
will be issued pursuant to an Indenture to be entered into between the Company
and the trustee to be named therein (the “Trustee”), substantially in the form
attached hereto as Exhibit B (the “Indenture”). The Investor will be entitled
to the benefits of the registration rights set forth in Exhibit C with respect
to the shares of Common Stock issuable upon conversion of the shares of
Preferred Stock, which terms contained in Exhibit C shall be deemed to be
incorporated by reference in and to constitute a part of this Agreement.

          In consideration of the representations, warranties, covenants and
agreements herein contained and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Company and the
Investor agree as follows:

          1. Sale and Purchase. Upon the basis of the warranties and
representations and subject to the other terms and conditions herein set forth,
the Company hereby sells to the Investor, and the Investor hereby purchases
from the Company, the aggregate number of shares of Preferred Stock set forth
opposite its name in Schedule A hereto at a purchase price of $10,000 per share
of Preferred Stock, for an aggregate purchase price of $100,000,000.

1

 

          2. Payment and Delivery. Payment of the purchase price for the shares of
Preferred Stock shall be made by wire transfer made payable to the order of the
Company or as it shall direct in federal (same day) funds, against delivery of
the certificates representing the number of shares of Preferred Stock to be
purchased to the Investor, at the offices of Shearman & Sterling LLP, in New
York, New York, or at such other place as may be agreed upon by the parties
hereto, at 10:00 A.M., eastern standard time, on March 19, 2004 (the
“Settlement Date”), concurrently with the delivery of the legal opinions of
Shearman & Sterling LLP, counsel to the Company, and Richards, Layton & Finger,
P.A., special Delaware counsel to the Company.

          3. Use of Proceeds. The proceeds received by the Company from the sale of
the Preferred Stock pursuant to the terms hereof will be used for general
corporate purposes, which may include strategic acquisitions.

          4. Representations and Warranties of the Company. The Company represents
and warrants to the Investor that as of the date hereof:

               (a) Each document filed by the Company with the U.S. Securities and
Exchange Commission (the “Commission”) since March 27, 2003, as listed in
Schedule B hereto, (i) complied when so filed in all material respects
with the Securities Exchange Act of 1934, as amended (the “Exchange Act”)
and the applicable rules and regulations of Commission thereunder and (ii)
when so filed did not contain any untrue statement of a material fact or
omit to state a material fact necessary to make the statements therein, in
the light of the circumstances under which they were made, not misleading.
The documents listed in Schedule B hereto, exclusive of any portions of
the respective filings that were furnished rather than filed under
applicable rules and regulations of the Commission, shall hereinafter be
referred to as, the “Specified Exchange Act Documents.” The Company has
provided or made available to the Investor such other information, as set
forth Schedule C hereto, which, together with the Specified Exchange Act
Documents, shall hereinafter referred to as the “Company Information”;

               (b) The statements in the Company’s draft Annual Report on Form 10-K,
dated March 4, 2004, under the caption “Part I. Item 1.
Business—Government Regulation” as of the date hereof, did not contain any
untrue statement of a material fact or omit to state any material fact
necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading;

               (c) As of December 31, 2003, the Company had an authorized and
outstanding capitalization as set forth in the Capitalization table
(including the footnotes thereto describing options, warrants and
instruments convertible into equity of the Company) attached hereto as
Schedule D (the “Capitalization Table”); all of the issued and outstanding
shares of capital stock of the Company have been duly and validly
authorized and issued and are fully paid and non-assessable and, except as
described or incorporated by reference in the Company Information, are
free of statutory or contractual preemptive and similar rights; since
December 31, 2003, through and including March 2, 2004, there has been no
issuances of any shares of capital stock of the Company, or any options,
warrants or securities exercisable for or convertible into capital stock
of the Company, other than such

2

 

shares that were issued pursuant to the Company’s employee benefits,
compensation or stock option plans (including stock option agreements
under any stock option plan of the Company) or that were issued upon the
exercise of securities described in Schedule D;

               (d) The Company has no significant subsidiaries (as defined in Rule
1-02 of Regulation S-X under the Exchange Act) except as listed in an
exhibit to the Company’s Annual Report on Form 10-K for the year ended
December 31, 2002 (such significant subsidiaries of the Company,
collectively, the “Subsidiaries”); (i)(A) each of Porex Corporation, WebMD
Inc., Medical Manager Health Systems, Inc. and Envoy Corporation
(collectively, the “Material Subsidiaries”) and the Company has been duly
incorporated and is validly existing as a corporation under the laws of
the jurisdiction of its incorporation, with all requisite corporate power
and authority to own its properties and conduct its business as described
in the Company Information and (B) with respect to each of the
Subsidiaries other than the Material Subsidiaries, such Subsidiary has
been duly incorporated and is validly existing as a corporation under the
laws of the jurisdiction of its incorporation, with all requisite
corporate power and authority to own its properties and conduct its
business as described in the Company Information except where such failure
to be so duly incorporated, validly existing and with all requisite
corporate power and authority would not have a Material Adverse Effect (as
defined below); (ii)(A) all of the issued shares of capital stock of each
Material Subsidiary have been duly and validly authorized and issued, are
fully paid and non-assessable and to the extent indicated in such exhibit
are owned directly or indirectly by the Company, free and clear of all
liens, encumbrances, equities or claims, except (x) for those encumbrances
disclosed in the Company Information, (y) for interests or liens held by
others as security for indebtedness of the Company or any Subsidiary, such
interests or liens as disclosed in the Company Information, and (x) for
transfer restrictions under applicable federal and state securities laws
and (B) with respect to each Subsidiary other than the Material
Subsidiaries, except to the extent that it would not have a Material
Adverse Effect (as defined below), all of the issued shares of capital
stock of each Subsidiary have been duly and validly authorized and issued,
are fully paid and non-assessable and to the extent indicated in such
exhibit are owned directly or indirectly by the Company, free and clear of
all liens, encumbrances, equities or claims, except (x) for those
encumbrances disclosed in the Company Information, (y) for interests or
liens held by others as security for indebtedness of the Company or any
Subsidiary, such interests or liens as disclosed in the Company
Information, and (z) for transfer restrictions under applicable federal
and state securities laws;

               (e) The Company and each of its Subsidiaries are duly qualified or
licensed to do business as foreign corporations and are in good standing
in each jurisdiction in which the conduct of their respective businesses
or their ownership or leasing of property requires such qualification or
license or good standing, except to the extent that the failure,
individually or in the aggregate, to be so qualified or licensed or be in
good standing would not have a material adverse effect on the operations,
business, prospects or condition (financial or otherwise) of the Company
and its subsidiaries, taken as a whole (a “Material Adverse Effect”);

3

 

               (f) Neither the Company nor any of the Subsidiaries is in material
breach of, or in default under (nor has any event occurred which with
notice, lapse of time, or both would constitute a material breach of, or
default under), its respective charter or by-laws, or any material
license, indenture, mortgage, deed of trust, bank loan or credit agreement
or other material evidence of indebtedness, or any material lease,
contract or other material agreement or instrument to which the Company or
any of the Subsidiaries is a party or by which any of them or their
respective properties may be bound or affected, or under any federal,
state, local or foreign law, regulation or rule or any decree, judgment or
order applicable to the Company or any of the Subsidiaries, and the
execution, delivery and performance of this Agreement and the execution
and filing of the Certificate, and the consummation of the transactions
contemplated hereby and thereby, including the issuance of the shares of
Preferred Stock, and any redemption thereof, the issuance of the shares of
Common Stock upon conversion of the Preferred Stock and the issuance of
the Subordinated Notes upon exchange of the Preferred Stock, will not
conflict with, or result in any material breach of or constitute a default
under (nor constitute any event which with notice, lapse of time, or both
would constitute a breach of, or default under), any provisions of the
charter or by-laws of the Company or any of the Subsidiaries or under any
provision of any material license, indenture, mortgage, deed of trust,
bank loan or credit agreement or other material evidence of indebtedness,
or any material lease, contract or other material agreement or instrument
to which the Company or any of the Subsidiaries is a party or by which any
of them or their respective properties may be bound or affected, or under
any federal, state, local or foreign law, regulation or rule or, to the
knowledge of the Company, any decree, judgment or order applicable to the
Company or any of the Subsidiaries;

               (g) This Agreement has been duly authorized, executed and delivered
by the Company;

               (h) The Indenture has been duly authorized by the Company and when
executed and delivered by the Company and the other parties thereto will
be a legal, valid and binding agreement of the Company, enforceable in
accordance with its terms, except as the enforceability thereof may be
limited by bankruptcy, insolvency, reorganization, moratorium or similar
laws affecting creditors’ rights generally and general principles of
equity;

               (i) The shares of Preferred Stock to be sold to the Investor pursuant
to the provisions of this Agreement have been duly authorized and, when
issued and paid for in accordance with the terms of this Agreement, will
be duly and validly issued, fully paid and nonassessable, and will be
issued free of statutory and contractual preemptive rights;

               (j) The shares of Common Stock issuable upon conversion of the
Preferred Stock have been duly authorized and validly reserved for
issuance upon conversion of the Preferred Stock, and upon conversion of
the Preferred Stock in accordance with their terms and the terms of the
Certificate will be issued free of statutory and contractual preemptive
rights, and such Common Stock, when so issued upon such conversion in
accordance with the terms of the Preferred Stock and the Certificate, will
be duly and validly issued and fully paid and nonassessable;

4

 

               (k) The Subordinated Notes have been duly authorized by the Company
for issuance to the Investor upon exchange of their shares of Preferred
Stock in accordance with the terms of the Indenture and the terms of the
Certificate and, when executed and delivered by the Company and duly
authenticated by the Trustee in accordance with the terms of the
Indenture, and delivered to the Investor in accordance with the terms of
the Certificate and the Indenture, will constitute legal, valid and
binding obligations of the Company, enforceable in accordance with their
terms, except as the enforceability thereof may be limited by bankruptcy,
insolvency, reorganization, moratorium or similar laws affecting
creditors’ rights generally and general principles of equity, and will be
entitled to the benefits of the Indenture;

               (l) Assuming the accuracy of the Investor’s representations and
warranties and compliance by the Investor with its covenants set forth
herein, no approval, authorization, consent or order of or filing with any
national, state or local governmental or regulatory commission, board,
body, authority or agency is required in connection with the issuance and
sale by the Company of the Preferred Stock, the shares of Common Stock
issuable upon conversion of the Preferred Stock and the Subordinated Notes
issuable upon exchange of the Preferred Stock, in each case as
contemplated hereby, other than (i) as may be required by federal and
state securities laws with respect to the Company’s obligations with
respect to the Investor’s registration rights set forth in Exhibit C
hereto and (ii) as have been made or obtained on or prior to the
applicable time of purchase;

               (m) Ernst & Young LLP, whose reports on the consolidated financial
statements of the Company and the Subsidiaries are included in the Company
Information, are independent public accountants with respect to the
Company as required by the Securities Act of 1933, as amended (the
“Securities Act”), and the applicable published rules and regulations
thereunder;

               (n) Each of the Company and the Subsidiaries has all necessary
licenses, authorizations, consents and approvals (collectively,
“Consents”) and has made all necessary filings required under any federal,
state, local or foreign law, regulation or rule (collectively, “Filings”)
and has obtained all necessary Consents from other persons, in order to
conduct its respective business, except where the failure to have any such
Consent or to have made any such Filing would not have a Material Adverse
Effect; neither the Company nor any of its Subsidiaries is in violation
of, or in default under, any such Consent or any federal, state, local or
foreign law, regulation or rule or, to the knowledge of the Company, any
decree, order or judgment applicable to the Company or any of the
Subsidiaries which violation or default would have a Material Adverse
Effect;

               (o) Except as described or incorporated by reference in the Company
Information, there are no actions, suits or proceedings pending or, to the
knowledge of the Company, threatened against the Company or any of the
Subsidiaries or any of their respective properties, at law or in equity,
or before or by any federal, state, local or foreign governmental or
regulatory commission, board, body, authority or agency which, if
determined in a manner adverse to the Company or any Subsidiary, would
result in a judgment, decree or order having a Material Adverse Effect;

5

 

               (p) Except as would not reasonably be expected to have a Material
Adverse Effect, the Company and each Subsidiary have filed on a timely
basis all necessary federal, state and foreign income, franchise and other
tax returns (other than returns being contested in good faith) and have
paid all taxes shown thereon as due (other than those being contested in
good faith or which are currently payable without penalty or interest),
and the Company has no knowledge of any tax deficiency which has been or
might be asserted against the Company or any Subsidiary; all material tax
liabilities are adequately provided for within the financial statements of
the Company in accordance with generally accepted accounting principles
(“GAAP”);

               (q) The Company and the Subsidiaries maintain insurance of the types
and in the amounts reasonably believed to be adequate for their business
and, to the knowledge of the Company, consistent with insurance coverage
maintained by similar companies in similar businesses, all of which
insurance is in full force and effect, except where the failure of any of
such insurance coverage to be in full force and effect would not have a
Material Adverse Effect;

               (r) Neither the Company nor the Subsidiaries are involved in any
labor dispute or disturbance nor, to the knowledge of the Company, is any
such dispute or disturbance threatened except, in each case, for disputes
or disturbances which would not, individually or in the aggregate, have a
Material Adverse Effect;

               (s) Except as described or incorporated by reference in the Company
Information, the Company and each Subsidiary owns or possesses such
licenses or other rights to use all patents, patent applications,
trademarks, trademark applications, service marks, service mark
applications, trade names, copyrights, manufacturing processes, formulae,
trade secrets, know-how, franchises, and other material intangible
property and assets (collectively, “Intellectual Property”) necessary to
the conduct of their respective businesses as conducted and as proposed to
be conducted as described or incorporated by reference in the Company
Information, except where the failure to do so would not have a Material
Adverse Effect; the Company has no knowledge that it or any Subsidiary
lacks or will be unable to obtain any rights or licenses to use any of the
Intellectual Property necessary to conduct the business now conducted or
proposed to be conducted by it as described or incorporated by reference
in the Company Information, except as described or incorporated by
reference in the Company Information and except where the failure to have
or obtain such rights or licenses would not have a Material Adverse
Effect; neither the Company nor any Subsidiary has received any written
notice of infringement or of conflict with rights or claims of others with
respect to any Intellectual Property which infringement or conflict would
have a Material Adverse Effect, except as described or incorporated by
reference in the Company Information, and the Company is not aware of any
patents of others which are infringed by the Company or any Subsidiaries
in such a manner as would have a Material Adverse Effect, except as
described or incorporated by reference in the Company Information;

               (t) The audited financial statements and related notes thereto of the
Company included or incorporated by reference in the Specified Exchange
Act Documents

6

 

present fairly in all material respects the consolidated financial
position of the Company and its Subsidiaries as of the dates indicated and
the results of operations and cash flows of the Company and its
Subsidiaries for the periods specified; such financial statements have
been prepared in conformity with GAAP applied on a consistent basis during
the periods involved;

               (u) As of the date hereof, subsequent to the respective dates as of
which information is stated or incorporated by reference in the Company
Information, there has not been (A) any material and unfavorable change in
the business, properties, prospects, regulatory environment, results of
operations or condition (financial or otherwise) of the Company and its
subsidiaries, taken as a whole, (B) any transaction entered into by the
Company or any of its subsidiaries, which is material to the Company and
its subsidiaries, taken as a whole, or (C) any obligation, contingent or
otherwise, directly or indirectly, incurred by the Company or any of its
subsidiaries which is material to the Company and its subsidiaries, taken
as a whole;

               (v) Except as described or incorporated by reference in the Company
Information, the Company and the Subsidiaries (i) are in compliance with
any and all applicable foreign, federal, state and local laws and
regulations relating to the protection of human health and safety, the
environment or hazardous or toxic substances or wastes, pollutants or
contaminants (collectively, “Environmental Laws”), (ii) have received all
permits, licenses or other approvals required of them under applicable
Environmental Laws to conduct their respective businesses and (iii) are in
compliance with all terms and conditions of any such permit, license or
approval, except where such noncompliance with Environmental Laws, failure
to receive required permits, licenses or other approvals or failure to
comply with the terms and conditions of such permits, licenses or
approvals would not have a Material Adverse Effect.

               (w) Neither the Company nor any affiliate (as defined in Rule 501(b)
of Regulation D under the Securities Act, an “Affiliate”) of the Company
has directly, or through any agent, (i) sold, offered for sale, solicited
offers to buy or otherwise negotiated in respect of, any security (as
defined in the Securities Act) which is or will be integrated with the
sale of the Preferred Stock in a manner that would require the
registration under the Securities Act of the Preferred Stock or (ii)
offered, solicited offers to buy or sold the Preferred Stock by any form
of general solicitation or general advertising (as those terms are used in
Regulation D under the Securities Act) or in any manner involving a public
offering within the meaning of Section 4(2) of the Securities Act;

               (x) Assuming the accuracy of the representations and warranties of
each of the Investor contained herein and compliance by the Investor with
its covenants set forth herein, it is not necessary in connection with the
offer, sale and delivery of the Preferred Stock to the Investor pursuant
to this Agreement, the issuance of shares of Common Stock issuable upon
conversion of the Preferred Stock or the issuance of Subordinated Notes
upon exchange of the Preferred Stock, to register the Preferred Stock,
such Common Stock or the Subordinated Notes under the Securities Act;

7

 

               (y) The Company is not and, after giving effect to the offering and
sale of the Preferred Stock and the application of the proceeds thereof as
described above in Section 3, will not be, required to register as an
“investment company” as defined in the Investment Company Act of 1940, as
amended;

               (z) Except as set forth in Exhibit D hereto and except for the
Investor’s registration rights set forth in Exhibit C hereto, there are no
contracts, agreements or understandings between the Company and any person
granting such person the right to require the Company to register any
securities with the Commission;

               (aa) Prior to the date hereof, neither the Company nor any of its
Affiliates has taken any action which is designed to or which has
constituted or which might have been expected to cause or result in
stabilization or manipulation of the price of any security of the Company
in connection with the sale of the Preferred Stock contemplated hereby;
and

               (bb) Within the preceding six months, neither the Company nor any
other person acting on behalf of the Company has offered or sold to any
person any shares of Preferred Stock, or any securities of the same or a
similar class as the shares of Preferred Stock, other than the shares of
Preferred Stock offered or sold to the Investor hereunder.

          5. Representations and Warranties of the Investor. The Investor hereby
represents and warrants to the Company as follows:

               (a)
Power and Authority. It has all necessary limited
liability company power and authority under all applicable provisions of
law to execute and deliver this Agreement to carry out its obligations
hereunder. All action on the Investor’s part required for the lawful
execution and delivery of this Agreement have been taken. Upon the
execution and delivery of this Agreement by the Investor, this Agreement
will be the legal, valid and binding agreement of such Investor;

               (b) No Registration. It understands that none of the shares of
Preferred Stock, or the shares of Common Stock issuable upon conversion
of the Preferred Stock or the Subordinated Notes issuable upon exchange
of the Preferred Stock has been registered under the Securities Act. It
also understands that the shares of Preferred Stock are being offered and
sold pursuant to an exemption from registration contained in the
Securities Act based in part upon the Investor’s representations
contained in this Agreement;

               (c) Standstill. It will not, during the period commencing the date
hereof through and including the sooner of (i) the date immediately
succeeding such date that the Company files its Annual Report on Form
10-K for the year ended December 31, 2003 and (ii) April 5, 2004,
directly or indirectly, alone on in concert with any other person, other
than the shares of Preferred Stock to be purchased hereby, acquire or
sell, offer to acquire or sell, or agree to acquire or sell whether
through market purchases, tender or exchange offer, acquisition of
control or otherwise, record or beneficial ownership, or any right to
acquire or vote, any of the Company’s shares of Common Stock;

8

 

               (d) Investor Bears Economic Risk. The Investor has substantial
experience in evaluating and investing in private placement transactions
of securities in companies similar to the Company so that it is capable
of evaluating the merits and risks of its investment in the Company and
has the capacity to protect its own interests. The Investor understands
that it must bear the economic risk of this investment indefinitely
unless the shares of Preferred Stock are registered pursuant to the
Securities Act, or an exemption from registration is available. The
Investor understands that the Company has no present intention of
registering the shares of Preferred Stock. The Investor also understands
that there is no assurance that any exemption from registration under the
Securities Act will be available and that, even if available, such
exemption may not allow the Investor to transfer all or any portion of shares of Preferred Stock under the circumstances, in the amounts or at
the times the Investor might propose;

               (e) Acquisition for Own Account. The Investor is acquiring the
Preferred Stock (and the shares of Common Stock issuable upon conversion
of the Preferred Stock or the Subordinated Notes issuable upon exchange
of the Preferred Stock, if applicable) for the Investor’s own account for
investment only, and not with a view towards its distribution, other than
in accordance with applicable law;

               (f) Investor Can Protect Its Interest. The Investor represents that
by reason of its, or of its management’s, business or financial
experience, the Investor has the capacity to protect its own interests in
connection with the transactions contemplated in this Agreement.
Further, the Investor has not undertaken any publication of any
advertisement in connection with the transactions contemplated in the
Agreement;

               (g) Accredited Investor. The Investor represents that it is an
accredited investor (“Accredited Investor”) within the meaning of
Regulation D under the Securities Act;

               (h) Company Information. The Investor has had an opportunity to
discuss the Company’s business, management and financial affairs with
certain members of management of the Company. The Investor has also had
the opportunity to ask questions of the Company and its management
regarding the terms and conditions of this investment;

               (i) Residence. If the Investor is an individual, then the Investor
resides in the state or province identified in the address of the
Investor set forth on Schedule A; if the Investor is a partnership,
corporation, limited liability company or other entity, then the office
or offices of the Investor in which its investment decision was made is
located at the address or addresses of the Investor set forth on Schedule
A;

               (j) Rule 144. The Investor understands that the shares of Preferred
Stock it is purchasing are characterized as “restricted securities” under
the federal securities laws inasmuch as they are being acquired from the
Company in a transaction not involving a public offering and that under
such laws and applicable regulations such securities may be resold
without registration under the Securities Act only in certain limited
circumstances. In this connection, the Investor represents that it is
familiar with Rule 144, as presently in

9

 

effect thereunder, and understands the resale limitations imposed
thereby and by the Securities Act;

               (k) No Broker Fee. The Investor represents and warrants that, other
than the fee payable to CalPERs/PCG Corporate Partners, LLC as set forth
in Schedule E hereof, no agent, broker, investment banker, person or firm
acting on behalf of or under the authority of such party hereto is or
will be entitled to any broker’s or finder’s fee or any other commission
directly or indirectly in connection with the transactions contemplated
herein; and

               (l) Hart-Scott-Rodino Act. The Investor will not hold (within the
meaning of the Hart-Scott-Rodino Antitrust Improvements Act of 1975, as
amended (the “HSR Act”)) any shares in the capital stock of the Company
other than the shares of Preferred Stock to be issued to the Investor
hereunder. The Investor intends to acquire such shares of Preferred
Stock solely for the purpose of investment and has no present intention
of participating in the formulation, determination or direction of the
basic business decisions of the Company under Subsection (c)(9) of the
HSR Act and rules promulgated thereunder.

          6. Certain Covenants of the Company. The Company hereby agrees that:

               (a) The Company will reserve and keep available at all times, free of
preemptive rights, such number of shares of Common Stock for the purpose
of enabling the Company to satisfy any obligations to issue such shares of
Common Stock upon conversion of the shares of Preferred Stock in
accordance with its terms;

               (b) Neither the Company nor any Affiliate will sell, offer for sale
or solicit offers to buy or otherwise negotiate in respect of any security
(as defined in the Securities Act) which could be integrated with the sale
of the shares of Preferred Stock in a manner which would require the
registration under the Securities Act of the shares of Preferred Stock;

               (c) The Company will not solicit or agree to solicit any offer to buy
or offer or sell the shares of Preferred Stock by means of any form of
general solicitation or general advertising (as those terms are used in
Regulation D) or in any manner involving a public offering within the
meaning of Section 4(2) of the Securities Act;

               (d) The Company will not take any action prohibited by Regulation M
under the Exchange Act in connection with the distribution of the shares
of Preferred Stock contemplated hereby;

               (e) So long as any other shares of Common Stock shall then be so
listed and so long as any shares of Preferred Stock are then outstanding,
the Company shall (i) use its reasonable best efforts to secure the
listing of the shares of Common Stock issuable upon conversion of the
Preferred Stock (collectively, the “Conversion Shares”) upon each national
securities exchange and automated quotation system, if any, upon which
shares of Common Stock are then listed (subject to official notice of
issuance) and (ii) maintain, so

10

 

long as any other shares of Common Stock shall then be so listed,
such listing of all Conversion Shares from time to time issuable under the
terms of the Preferred Stock. So long as any other shares of Common Stock
shall then be so listed and so long as any shares of Preferred Stock are
then outstanding, the Company shall maintain the Common Stock’s
authorization for quotation or listing on The New York Stock Exchange, the
American Stock Exchange, Inc. or The Nasdaq National Market or SmallCap
Market, as applicable. The Company shall pay all fees and expenses in
connection with satisfying its obligations under this Section 6(e); and

               (f) The Company will not, without the prior written consent of
holders of 75% of the shares of Preferred Stock then outstanding, (i)
issue any additional shares of Preferred Stock, (ii) create any other
class or series of Capital Stock, the terms of which expressly provide
that such class or series ranks senior to the Preferred Stock as to rights
upon liquidation, winding-up, dividends or dissolution of the Company or
(iii) create any class or series of Parity Stock (as such term is defined
in the Certificate).

               (g) The Company agrees to use its reasonable best efforts to amend,
subject to the approval thereof by the holders of (i) a majority of the
shares of Common Stock then outstanding, voting as a separate class, and
(ii) a majority of the shares of Preferred Stock then outstanding, voting
as a separate class, the Certificate of Incorporation of the Company at
the next meeting of the stockholders of the Company to provide that the
shares of Preferred Stock shall have the right to vote, on an as-converted
basis, on matters that are put to vote of holders of shares of Common
Stock of the Company with such number of votes as the Holders shall have
had the right to receive had such Holder converted its Preferred Stock
into Common Stock immediately prior to the event date, and to provide that
the Company will not, without the prior written consent of holders of 75%
of the shares of Preferred Stock then outstanding, voting as a separate
class, undertake any of the actions set forth in Section 6(f) above. In
the event that such amendments to the Certificate of Incorporation are not
obtained at such meeting of stockholders, the Company agrees that it will
pay to the Investor $250,000.

               (h) The Company agrees that it will pay to CalPERs/PCG Corporate
Partners, LLC the fees set forth in Schedule E hereof.

               (i) In the event of any offer made by the Company or any Affiliate of
the Company, at the option of the Company, to repurchase or acquire less
than all of the shares of Preferred Stock (a “Repurchase Offer”), the
Investor shall be entitled to written notice of such Repurchase Offer no
less than 15 days prior to the effective date of the repurchase that is
the subject of the Repurchase Offer. Such notice shall state the price
and all other terms and conditions upon which the Repurchase Offer is
made, and the Investor shall be entitled to accept such Repurchase Offer
and participate, on a pro rata basis, in such repurchase.

11

 

          7. Restrictions on Transfer; Investor Covenants. The Investor hereby
agrees that:

               (a) So long as the Investor owns any shares of Preferred Stock, it
will not transfer, directly or indirectly, by operation of law or
otherwise (including by merger), whether through offers to sell, contracts
to sell, pledges, sales of any option or contract to purchase, grants of
any option, right or warrant to purchase, the lending of or the entering
into any swap or other agreements involving one or more parties, commonly
known as “hedging,” in each case, that transfers to another, in whole or
in part, any of the economic consequences of ownership of Preferred Stock
or shares of Common Stock, whether any of such transactions is to be
settled by delivery of shares of Preferred Stock, Common Stock or such
other securities, in cash or otherwise. In addition, the Investor shall
not sell, transfer or otherwise dispose of (“Transfer”) its Preferred
Stock other than in accordance with applicable law, and then only:

               (i) to “qualified institutional buyers” in compliance with the
exemption from registration provided by Rule 144A under the
Securities Act (“Rule 144A”), to members or partners of the Investor
who are Accredited Investors, to other Accredited Investors
reasonably acceptable to the Company or otherwise in accordance with
Schedule F hereto;

               (ii) in aggregate dollar denominations (which shall be an
amount equal to the aggregate number of shares of Preferred Stock
multiplied by the Liquidation Preference of such Preferred Stock as
set forth in the Certificate) of at least $10 million, or integral
multiples thereof, to any single purchaser;

               (iii)
upon delivery to the Company of (1) a certificate duly
executed by the Investor, as transferor, together with an opinion of
counsel reasonably satisfactory to the Company, stating that such
Transfer complies with the Securities Act, (2) an acknowledgement
and agreement of the transferee to be bound by the terms and
conditions of this Section 7 as if such transferee were an Investor
and party to this Agreement, (3) a written statement executed by the
transferee certifying that such transferee currently does not have any unwound position in any transaction that
otherwise would be prohibited by Section 7(a), provided that in the
event the transferee is an entity of which the purchaser is a
division (the “Purchasing Division”) of a diversified financial
institution that engages separately in investment and trading
activities, such transferee institution will be exempt from Section
7(a) and from such certification in respect solely of the activities
of the divisions of the transferee other than the Purchasing
Division that are (A) separately operated as a corporate matter and
(B) not permitted to, and not in fact engaging, or proposing to
engage in, the activities described in Section 7(a) on behalf of or
on concert with the Purchasing Division; and (4) a written
representation from such transferee to the effect set forth in
Sections 5(d), 5(e), 5(f) and 5(g) hereof; and

12

 

               (iv) otherwise in compliance with and subject to the terms and
conditions set forth in this Section 7, including the right of the
Company to effect a repurchase pursuant to Section 7(c) below;

               (b) in the event that the Investor intends to effect any Transfer, it
shall provide prior written notice (the “Transfer Notice”) thereof to the
Company, at least 5 trading days prior to the date of the proposed
Transfer (the “Transfer Date”), which Transfer Notice shall state the
aggregate number of shares, aggregate dollar amount and the stock
certificate number of the Preferred Stock proposed to be Transferred (the
“Transfer Shares”);

               (c) from and after the Transfer Date, the Company shall have the
option to repurchase, at any time and from time to time, out of lawfully
available funds, all or a portion of the shares of Preferred Stock then
outstanding that are Transfer Shares (other than Transfer Shares subject
to Schedule F and other than Transfer Shares acquired by members or
partners of the Investor who are Accredited Investors in accordance with
this Section 7), at a repurchase price per share equal to 105% of the
Liquidation Preference of the Preferred Stock, as set forth in the
Certificate;

               (d) shares of Common Stock issued upon conversion of the Preferred
Stock, and Subordinated Notes issued upon exchange of the Preferred Stock,
shall bear appropriate legends as to restrictions on transfer (a
“Restrictive Legend”);

               (e) upon the transfer, exchange or replacement of any Common Stock or
Subordinated Notes bearing the Restrictive Legend, the Company (or its
transfer agent or registrar) shall deliver only Common Stock or
Subordinated Notes, as applicable, that bear the Restrictive Legend until
such time as there shall have been delivered to the Company an opinion of
counsel reasonably satisfactory to the Company to the effect that the
Restrictive Legend nor the related restrictions on transfer are required
in order to maintain compliance with the provisions of the Securities Act;
and

               (f) the Investor will not provide, disclose or otherwise divulge any
“Confidential Information” (as such term is defined in the Confidentiality
Agreement, dated January 5, 2004, between the Company and Pacific
Corporate Group (the “Confidentiality Agreement”)) to any transferee or
potential transferee of any shares of Preferred Stock or shares of Common
Stock held by it without the prior written consent of the Company.

          The Company agrees that nothing in the provisions of this Section 7 shall
be deemed to prohibit or restrict any outright sale of both record and
beneficial ownership of the Common Stock issuable upon conversion of the
Preferred Stock, subject only to applicable law.

          8. Indemnification.

               (a) The Company agrees to indemnify, defend and hold harmless the
Investor, its respective directors and officers, and any person who
controls the Investor within the meaning of Section 15 of the Securities
Act or Section 20 of the Exchange Act (each, an “Investor Indemnified
Party”), from and against any loss, damage, expense,

13

 

liability or claim (including the reasonable cost of investigation)
which such Investor Indemnified Party may incur under the Securities Act,
the Exchange Act or otherwise, insofar as such loss, damage, expense,
liability or claim arises out of or is based upon any misrepresentation or
breach of any representation, warranty, covenant or agreement by the
Company in this Agreement.

               (b) The Investor agrees to indemnify, defend and hold harmless the
Company, its directors and officers, and any person who controls the
Company within the meaning of Section 15 of the Securities Act or Section
20 of the Exchange Act (each, a “Company Indemnified Party”), from and
against any loss, damage, expense, liability or claim (including the
reasonable cost of investigation) which such Company Indemnified Party may
incur under the Securities Act, the Exchange Act or otherwise, insofar as
such loss, damage, expense, liability or claim arises out of or is based
upon any misrepresentation or breach of any representation, warranty,
covenant or agreement by the Investor in this Agreement.

               (c) If any action, suit or proceeding (each, a “Proceeding”) is
brought against any person in respect of which indemnity may be sought
pursuant to subsection (a) or (b) of this Section 7, such person (the
“Indemnified Party”) shall promptly notify the person against whom such
indemnity may be sought (the “Indemnifying Party”) in writing of the
institution of such Proceeding and such Indemnifying Party shall
assume the defense of such Proceeding, including the employment of counsel
reasonably satisfactory to such Indemnified Party and payment of all fees
and expenses; provided, however, that the omission to so notify such
Indemnifying Party shall not relieve such Indemnifying Party from any
liability which it may have to such Indemnified Party or otherwise. Such
Indemnified Party shall have the right to employ its own counsel in any
such case, but the fees and expenses of such counsel shall be at the
expense of such Indemnified Party unless the employment of such counsel
shall have been authorized in writing by such Indemnifying Party in
connection with the defense of such Proceeding or such Indemnifying Party
shall not have employed counsel to have charge of the defense that is
reasonably satisfactory to the Indemnified Party of such Proceeding within
60 days of the receipt of notice thereof or such Indemnified Party shall
have reasonably concluded upon written advice of counsel that there may be
defenses available to it that are different from, additional to, or in
conflict with those available to such Indemnifying Party (in which case
such Indemnifying Party shall not have the right to direct that portion of
the defense of such Proceeding on behalf of such Indemnified Party, but
such Indemnifying Party may employ counsel and participate in the defense
thereof but the fees and expenses of such counsel shall be at the expense
of such Indemnifying Party), in any of which events such reasonable fees
and expenses shall be borne by such Indemnifying Party and paid as
incurred (it being understood, however, that such Indemnifying Party shall
not be liable for the expenses of more than one separate counsel in any
one Proceeding or series of related Proceedings together with reasonably
necessary local counsel representing the Indemnified Parties who are
parties to such Proceeding). An Indemnifying Party shall not be liable
for any settlement or compromise of any such Proceeding effected without
its written consent, but if settled or compromised with the written
consent of such Indemnifying Party, such Indemnifying Party agrees to
indemnify and hold harmless an Indemnified Party from and against any loss
or liability by

14

 

reason of such settlement. An Indemnifying Party shall not, without
the prior written consent of any Indemnified Party, effect any settlement
of any pending or threatened Proceeding in respect of which such
Indemnified Party is or could have been a party and indemnity could have
been sought hereunder by such Indemnified Party, unless such settlement
includes an unconditional release of such Indemnified Party from all
liability on claims that are the subject matter of such Proceeding and
does not include an admission of fault, culpability or a failure to act,
by or on behalf of such Indemnified Party.

               (d) The indemnity agreements contained in this Section 7 and the
covenants, warranties and representations of the Company and the Investors
contained in this Agreement shall remain in full force and effect
(regardless, with respect to representations and warranties of the
Company, of any investigation made by on behalf of the Investor, its
respective directors or officers or any person who controls the Investor
within the meaning of Section 15 of the Securities Act or Section 20 of
the Exchange Act, or by or on behalf of the Company, its directors and
officers or any person who controls the Company within the meaning of
Section 15 of the Securities Act or Section 20 of the Exchange Act), and
shall survive any termination of this Agreement and the issuance and
delivery of the shares of Preferred Stock.

          9. Effectiveness. This Agreement shall become effective upon the
execution and delivery hereof by the parties hereto. The respective
indemnities, agreements, representations, warranties and other statements of
the Company and the Investor, as set forth in this Agreement or made by or on
behalf of them, respectively, pursuant to this Agreement, shall remain in full
force and effect, regardless of any investigation (or any statement as to the
results thereof) made by or on behalf of the Investor or any controlling person
of the Investor, or the Company, or any officer or director or controlling
person of the Company, and shall survive delivery of and payment for the shares
of Preferred Stock.

          10. Fees and Expenses. Each party shall pay all costs and expenses that
it incurs with respect to the negotiation, execution, delivery and performance
of the Agreement; provided, however, that the Company shall reimburse the
Investor for reasonable and documented out-of-pocket expenses incurred in
connection with the due diligence and legal review related to the transaction
contemplated herein, not to exceed $750,000, on the Settlement Date.

          11. Amendment and Waiver.

               (a) This Agreement may be amended or modified only upon the written
consent of the Company and holders of at least a majority of the shares of
Preferred Stock outstanding (treated as if converted and including any
shares of Common Stock into which the Preferred Stock have been
converted).

               (b) The obligations of the Company and the rights of the holders of
the shares of Preferred Stock under the Agreement may be waived only with
the written consent of the holders of at least a majority of the shares of
Preferred Stock outstanding (treated as if converted and including any
shares of Common Stock into which the Preferred Stock have been
converted).

15

 

          12. Delays or Omissions. It is agreed that no delay or omission to
exercise any right, power or remedy accruing to any party, upon any breach,
default or noncompliance by another party under this Agreement shall impair any
such right, power or remedy, nor shall it be construed to be a waiver of any
such breach, default or noncompliance, or any acquiescence therein, or of or in
any similar breach, default or noncompliance thereafter occurring. It is
further agreed that any waiver, permit, consent or approval of any kind or
character on any Investor’s part of any breach, default or noncompliance under
this Agreement or any waiver on such party’s part of any provisions or
conditions of the Agreement must be in writing and shall be effective only to
the extent specifically set forth in such writing. All remedies, either under
this Agreement, by law, or otherwise afforded to any party, shall be cumulative
and not alternative.

          13. Headings. The titles of the sections and subsections of the Agreement
are for convenience of reference only and are not to be considered in
construing this Agreement.

          14. Parties in Interest. The Agreement herein set forth has been and is
made solely for the benefit of the Investor and the Company and the controlling
persons, directors and officers referred to in Section 7 hereof, and their
respective successors, assigns, executors and administrators. No other person,
partnership, association or corporation (other than a purchaser who acquires
Preferred Stock or Common Stock pursuant to Section 7 hereof) shall acquire or
have any right under or by virtue of this Agreement.

          15. Entire Agreement. This Agreement, the Exhibits and Schedules hereto,
and the other documents delivered pursuant hereto or referred to herein,
including the terms and provisions of the Confidentiality Agreement, constitute
the full and entire understanding and agreement between the parties with regard
to the subjects hereof and no party shall be liable or bound to any other in
any manner by any representations, warranties, covenants and agreements except
as specifically set forth herein and therein.

          16. Counterparts. This Agreement may be signed by the parties in any
number of counterparts that together shall constitute one and the same
agreement among the parties. Delivery of an executed counterpart by facsimile
shall be effective as delivery of a manually executed counterpart thereof.

          17. Notices. Except as otherwise herein provided, all statements,
requests, notices and agreements shall be in writing or by facsimile and, if to
the Investor, shall be sufficient in all respects if delivered or sent to
CalPERs/PCG Corporate Partners, LLC, c/o Pacific Corporate Group LLC, 1200
Prospect Street, Suite 200, La Jolla, CA 92037, Direct Phone: +1 (858)
456-3113, Direct Fax: +1 (858) 456-6018, Attention: Monte Brem, with a copy to
Gibson, Dunn & Crutcher LLP, 333 South Grand Avenue, Los Angeles, California
90071, Attention Jennifer Bellah Maguire, Partner, facsimile no. (213)
229-7520, and, if to the Company, shall be sufficient in all respects if
delivered or sent to the Company at the offices of the Company at 669 River
Drive, Center 2, Elmwood Park, New Jersey 07407-1361, Attention: Andrew C.
Corbin, Executive Vice-President and Chief Financial Officer, facsimile no.
(201) 703-3401, with a copy to Shearman & Sterling LLP, 599 Lexington Avenue,
New York, New York 10022, Attention: Creighton O’M Condon, Partner, facsimile
no.: (212) 848-7179.

16

 

          18. Governing Law and Construction. THIS AGREEMENT SHALL BE GOVERNED BY,
AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK, WITHOUT
REGARD TO CONFLICTS OF LAWS PRINCIPLES. THE SECTION HEADINGS IN THIS AGREEMENT
HAVE BEEN INSERTED AS A MATTER OF CONVENIENCE OF REFERENCE AND ARE NOT A PART
OF THIS AGREEMENT.

          19. Submission to Jurisdiction. Except as set forth below, no Proceeding
may be commenced, prosecuted or continued in any court other than the courts of
the State of New York located in the City and County of New York or in the
United States District Court for the Southern District of New York, which
courts shall have jurisdiction over the adjudication of such matters, and the
Company hereby consents to the jurisdiction of such courts and personal service
with respect thereto. The Company hereby consents to personal jurisdiction,
service and venue in any court in which any Proceeding arising out of or in any
way relating to this Agreement is brought by any third party against the
Investor. The Company and the Investor hereby waive all right to trial by jury
in any Proceeding (whether based upon contract, tort or otherwise) in any way
arising out of or relating to this Agreement. The Company agrees that a final
judgment in any such Proceeding brought in any such court shall be conclusive
and binding thereupon and may be enforced in any other court in the
jurisdiction to which the Company is or may be subject by suit upon such
judgment.

17

 

          If the foregoing correctly sets forth the understanding between the
Company and the Investor, please so indicate in the space provided below for
the purpose, whereupon this letter and your acceptance shall constitute a
binding agreement between the Company and the Investor.

	 	 	 	 	 
	 	 	Very truly yours,
	 	 	WEBMD CORPORATION
	 	 	 	 	 
	 	 	
By:	 	
/s/ Andrew C. Corbin
	 	 
	 	 	 	

	 	 	 	
Name:
	
 Andrew C. Corbin

	 	 	 	
Title:	
 Executive Vice-President and

 Chief Financial Officer

Accepted and agreed to as of the date first above written:

CALPERS/PCG CORPORATE PARTNERS, LLC

By:  PCG Corporate Partners Investments LLC

Its:  Manager

     By:  Pacific Corporate Group Holdings, LLC

     Its:  Managing Member

    

            /s/
Christopher Bower
 

Name:  Christopher
Bower

Title:    Chief
Executive Officer

 

 

EXHIBIT A

Certificate of Designation

[See Exhibit 3.2 to this Annual Report on Form 10-K]

A-1

 

Exhibit B

Form of Indenture

[See Exhibit 3.2 to this Annual Report on Form 10-K]

B-1

 

Exhibit C

Registration Rights of the Investor

With Respect to Shares of Common Stock Underlying the Preferred Stock

ARTICLE 1

DEFINITIONS

     1.1 Certain Definitions. Capitalized terms used and not otherwise defined
herein shall have the meanings assigned to them in the Purchase Agreement of
which this Exhibit C is a part. As used in this Exhibit C:

          (a) “Affiliate” means, with respect to any Person, any other Person which
directly or indirectly, by itself or through one or more intermediaries,
controls, or is controlled by, or is under direct or indirect common control
with, such Person. For purposes of this Exhibit C, none of the Investors nor
any of their Affiliates shall be deemed an Affiliate of the Company, and
neither the Company nor any of its Affiliates shall be deemed an Affiliate of
any Investor.

          (b) “Business Day” is a day other than a Legal Holiday.

          (c) “Certificate” means the Certificate of Designations pursuant to which
the Preferred Stock is issued.

          (d) “Common Stock” means the shares of common stock, par value $0.0001 per
share, of the Company.

          (e) “control” (including the term “controlled by”), with respect to the
relationship between or among two or more Persons, means the possession,
directly or indirectly or as trustee, personal representative or executor, of
the power to direct or cause the direction of the affairs or management of a
Person, whether through the ownership of voting securities, as trustee,
personal representative or executor, by contract or otherwise, including,
without limitation, the ownership, directly or indirectly, of securities having
the power to elect a majority of the board of directors or similar body
governing the affairs of such Person.

          (f) “Demand Requests” shall have the meaning set forth in Section 2.1(a)
hereof.

          (g) “Demand Registration Statement” shall have the meaning set forth in
Section 2.1(a) hereof.

          (h) “Effectiveness Period” shall have the meaning set forth in Section
2.2(c) hereof.

          (i) “Exchange Act” means the Exchange Act of 1934, as amended.

          (j) “Form S-3” means such form under the Securities Act as in effect on
the date hereof or any registration form under the Securities Act subsequently
adopted by the SEC which permits inclusion or incorporation of substantial
information by reference to other documents filed by the Company with the SEC.

 

 

          (k) “Holders” means the Investors and Permitted Holders, if any.

          (l) “Indemnified Persons” shall have the meaning set forth in Section
2.4(a) hereof.

          (m) “Investors” shall mean the parties identified as such in the Purchase
Agreement.

          (n) “Legal Holiday” is a Saturday, a Sunday or a day on which banking
institutions are not required to be open in the City of New York, in the State
of New York or in the city in which the Registrar or the applicable agent
administers its corporate trust business.

          (o) “Notice Holders” shall have the meaning set forth in Section 2.1(a)
hereof.

          (p) “Person” or “person” means any individual, corporation, partnership,
limited liability company, joint venture, association, joint-stock company,
trust, unincorporated organization or government or other agency or political
subdivision thereof.

          (q) “Permitted Holder” means any Person to whom an Investor has assigned
any of its rights under this Exhibit C in accordance with Section 2.6 of this
Exhibit C.

          (r) “Purchase Agreement” means the purchase agreement, dated March 4,
2004, between the Company and the Investors named therein.

          (s) “Preferred Stock” means the Convertible Redeemable Exchangeable
Preferred Stock, par value $0.0001 per share, of the Company.

          (t) “Register,” “registered” and “registration” refer to a registration
effected by preparing and filing a registration statement in compliance with
the Securities Act, and the declaration or ordering of the effectiveness of
such registration statement.

          (u) “Registrable Securities” means all or any portion of (i) the shares of
Common Stock that are issued upon conversion of the Preferred Stock in
accordance with its terms (the “Underlying Common Stock”) and (ii) any shares
of Common Stock that are issued in satisfaction of the Company’s right to
redeem shares of Preferred Stock in accordance with the terms of the
Certificate (the “Redemption Common Stock”), until the earlier of (1) the date
on which such Underlying Common Stock or Redemption Common Stock, as the case
may be, has been registered under the Securities Act and disposed of pursuant
to an effective registration statement or (2) the date on which all legends restricting transfers of such
Underlying Common Stock or Redemption Common Stock have been removed from the
related certificates and, if requested by the Holder, the Company shall have
delivered to such Holder an opinion of outside counsel reasonably acceptable to
such Holder to the effect that the removal of such legend is in accordance with
applicable securities laws.

          (v) “SEC” means the U.S. Securities and Exchange Commission.

C-2

 

          (w) “Securities Act” means the Securities Act of 1933, as amended.

          (x) “Suspension Condition” shall have the meaning set forth in Section
2.2(f) hereof.

          (y) “Suspension Period” shall have the meaning set forth in Section 2.2(f)
hereof.

ARTICLE 2

REGISTRATION RIGHTS

     2.1 Demand Registration.

          (a) Subject to Section 2.2(a), if, at any time on or after March 19, 2006,
the Company shall receive from the Holders, a written request signed by the
Holders of at least 40% of the then outstanding Underlying Common Stock and
Redemption Common Stock, if any, determined as one class (a “Demand Request”),
which Demand Request shall be forwarded by the Company to all Holders, that the
Company register under the Securities Act all or any portion of the Registrable
Securities, then the Company shall use its reasonable best efforts to cause the
Registrable Securities specified in such Demand Request to be registered as
soon as reasonably practicable so as to permit the offering and sale thereof by
such Holders (the “Notice Holders”) and, in connection therewith, shall, as
soon as reasonably practicable, but in any event not later than sixty (60) days
(excluding any days which occur during the period of a permitted Suspension
Condition pursuant to Section 2.2(f) below) after receipt of a Demand Request,
prepare and file with the SEC a registration statement (which may be a shelf
registration statement on Form S-3, if such Form S-3 is available for use by
the Company) to effect the registration and distribution of the Registrable
Securities pursuant to Rule 415(a)(1)(i) under the Securities Act (a “Demand
Registration Statement”); provided however that in no event shall the Company
be obligated to prepare and file any Demand Registration Statement with respect
to less than 20% of the shares of Registrable Securities originally issued;
provided further that in the event that the Company or its successor thereto
ceases to be a company subject to or in compliance with Section 13 or 15(d) of
the Exchange Act, any such Demand Request may, at the option of the Holders and
subject to the provisions hereof, be delivered to the Company immediately.

          (b) Each Demand Request shall: (i) specify the number of Registrable
Securities intended to be offered and sold by the Notice Holders pursuant
thereto; (ii) describe the nature or method of distribution of such Registrable
Securities pursuant to such Demand Registration Statement; and (iii) contain
the undertaking of the Notice Holders to provide all such information and
materials and take all such actions as may be required in order to permit the
Company to comply with all applicable requirements of the Securities Act, the
Exchange Act and the rules and regulations of the SEC thereunder.

     2.2 Registration Procedures, Rights and Obligations. The procedures to be
followed by the Company and the Holder, and the respective rights and
obligations of the Company and the Holder, with respect to the preparation,
filing and effectiveness of the Demand Registration Statement and the
distribution of Registrable Securities pursuant thereto, are as follows:

C-3

 

          (a) The Holders, collectively, shall be entitled to make a maximum of two
(2) Demand Requests that result in the actual registration of Registrable
Securities.

          (b) Any Demand Request that does not result in the corresponding Demand
Registration Statement being declared effective by the SEC shall not be counted
against the maximum of two (2) Demand Requests to which the Holders are
entitled. Any Demand Request that is withdrawn by the Holders for any reason
(other than as a result of a materially adverse development on the part of the
Company) shall count for purposes of determining the Demand Request to which
the Holders are entitled.

          (c) The Company shall use its reasonable best efforts to cause the Demand
Registration Statement to be declared effective by the SEC promptly and to keep
such Demand Registration Statement continuously effective until the earliest to
occur of: (i) the sale or other disposition of all the Registrable Securities
so registered; and (ii) the date which is 180 days from the date on which such
Demand Registration Statement was declared effective by the SEC (the
“Effectiveness Period”). The Company shall prepare and file with the SEC such
amendments and supplements to the Demand Registration Statement and prospectus
used in connection therewith as may be necessary to make and to keep such
Demand Registration Statement effective and to comply with the provisions of
the Securities Act with respect to the sale or other disposition of all
Registrable Securities proposed to be distributed pursuant thereto during the
Effectiveness Period. The Company shall, to the extent reasonably practicable,
at least three (3) Business Days prior to filing any Demand Registration
Statement or prospectus or any amendments or supplements thereto, furnish to
the Notice Holders and its counsel copies of all such documents proposed to be
filed and the Notice Holders shall have the opportunity to comment on any
information pertaining solely to it and its plan of distribution that is
contained therein and the Company shall make the corrections reasonably
requested by the Notice Holders with respect to such information prior to
filing any such Demand Registration Statement or amendment.

          (d) The Notice Holders named as selling securityholders in any Demand
Registration Statement shall not be entitled to offer or sell any securities
pursuant to such Demand Registration Statement unless and until the Company has
made all required filings with the SEC with respect to the distribution of the
Registrable Securities, such filings have become effective, and the Company has
notified the Notice Holders so named of the foregoing and that no Suspension
Condition then exists. The Company agrees to make all of such required
filings, if any, and to use its reasonable best efforts to cause them to so
become effective.

          (e) Notwithstanding any other provisions of this Exhibit C, in the event
that the Company receives the Demand Request, at a time when the Company (i)
has commenced, or has a bona fide intention to commence, a public securities
offering transaction, or (ii) non-public material information not otherwise
then required by law to be publicly disclosed regarding the Company exists, the
immediate disclosure of which would be significantly disadvantageous to the
Company, then the Company shall be entitled to suspend, for an aggregate period
of up to thirty (30) days after the receipt by the Company of such Demand
Request, the filing of any Demand Registration Statement (each of the events or
conditions referred to in clauses (i) and (ii) of this sentence is hereinafter
referred to as a “Blackout Event”).

C-4

 

          (f) Notwithstanding any other provision of this Exhibit C, in the event
that the Company’s board of directors determines that: (i) the prospectus
constituting a part of any Demand Registration Statement covering the
distribution of any Registrable Securities contains an untrue statement of a
material fact or omits to state a material fact required to be stated therein
or necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading; or (ii) an offering of Registrable
Securities would materially and adversely affect or interfere with any proposed
material acquisition, disposition or other similar corporate transaction or
event involving the Company (each of the events or conditions referred to in
clauses (i) and (ii) of this sentence is hereinafter referred to as a
“Suspension Condition”), then the Company shall have the right to suspend the
filing or effectiveness of any Demand Registration Statement required pursuant
to Section 2.1, or to suspend any distribution of Registrable Securities
pursuant thereto for an aggregate period of up to forty-five (45) days (such
period hereinafter referred to as a “Suspension Period”) after the delivery of
notice from the Company to the Holders of the existence of any Suspension
Condition; provided that the 180-day period during which a Demand Registration
Statement is required to be declared effective in accordance with the terms of
this Exhibit C shall be extended by the duration of any Suspension Period and
any additional period during which the amendment or supplement to the
prospectus relating to such Demand Registration Statement referred to below has
not been delivered. Upon receipt of notice from the Company of the existence
of any Suspension Condition, the Holders shall forthwith discontinue to offer
or sell Registrable Securities (in the event that such Demand Registration
Statement has been declared effective at the time the Notice Holders receive
notice that a Suspension Condition has arisen). In the event that the Notice
Holders had previously commenced or were about to commence the distribution of
Registrable Securities pursuant to a prospectus under an effective Demand
Registration Statement then the Company shall, promptly after the Suspension
Condition ceases to exist, make available to the Notice Holders an amendment or
supplement to such prospectus. If so directed by the Company, the Notice
Holders shall deliver to the Company all copies, other than permanent file
copies then in the Notice Holders’ possession, of the most recent prospectus
covering such Registrable Securities at the time of receipt of such notice.

          (g) The Company shall promptly notify the Notice Holders of any stop
order, injunction or other order or requirement of the SEC issued or, to the
Company’s knowledge, threatened to be issued by the SEC with respect to any
Demand Registration Statement in which such Notice Holders are named as
selling securityholders and will use its reasonable best efforts to prevent the
entry of such stop order, injunction or other order or requirement of the SEC
or to remove it if entered at the earliest possible date.

          (h) The Company shall furnish to the Notice Holders such number of copies
of any prospectus, including any preliminary prospectus and any amended or
supplemented prospectus (including in each case all exhibits), in conformity
with the requirements of the Securities Act, in which such Notice Holders are
named as selling securityholders, as such Notice Holders shall reasonably
request in order to effect the offering and sale of any Registrable Securities
to be offered and sold.

          (i) The Company shall use its reasonable best efforts to register or
qualify the Registrable Securities covered by the Registration Statement under
the state securities or “blue sky” laws of such jurisdictions as the Notice
Holder shall reasonably request, to keep such

C-5

 

registration or qualification in effect for so long as such Registration
Statement remains in effect, and to take any other action which may be
reasonably necessary to enable the Notice Holder to consummate the disposition
in such jurisdiction of the Registrable Securities owned by the Notice Holder
until the earlier to occur of: (i) the sale or other disposition of the
Registrable Securities so registered; and (ii) in the case of a Demand
Registration Statement, until the date which is 180 days from the date on which
such Registration Statement was declared effective by the SEC; provided,
however, that the Company shall not be required to take any action that would
subject it to the general jurisdiction of the courts of any jurisdiction in
which it is not so subject or to qualify as a foreign corporation in any
jurisdiction where the Company is not so qualified.

          (j) The Company shall use its reasonable best efforts to prevent the
issuance or obtain the withdrawal of any order suspending the effectiveness of
any Demand Registration Statement at the earliest possible time.

     2.3 Expenses. All fees and expenses incurred in connection with any
Demand Registration Statement, including without limitation all registration,
filing and qualification fees, printers’ and accounting fees, fees of the
National Association of Securities Dealers, Inc. or listing fees, and all fees
and expenses of complying with state securities or “blue sky” laws and the fees
and disbursements of counsel for the Company shall be paid by the Company,
except that the Holders shall bear and pay any and all fees and expenses
incurred in respect of counsel or other advisors to the Holders.

     2.4 Indemnification.

          (a) In the case of any offering registered pursuant to this Exhibit C, to
the extent permitted by law, the Company shall indemnify and hold harmless each
Notice Holder named as a selling securityholder in the Demand Registration
Statement and each of its officers and directors and each person who controls
such Notice Holder within the meaning of Section 15 of the Securities Act or
Section 20 of the Exchange Act (each such person being sometimes referred to as
an “Indemnified Person”) against any losses, claims, damages, expenses or
liabilities, joint or several, to which such Indemnified Person may become
subject under the Securities Act, the Exchange Act or otherwise, insofar as
such losses, claims, damages, expenses or liabilities (or actions in respect
thereof) arise out of or are based upon an untrue statement or alleged untrue
statement of a material fact contained in any Demand Registration Statement
under which such Registrable Securities are to be registered under the
Securities Act, or any prospectus contained therein or furnished by the Company
to any Indemnified Person, or any amendment or supplement thereto, or arise out
of or are based upon any omission or alleged omission to state therein a
material fact required to be stated therein or necessary to make the statements
therein, in the light of the circumstances under which they were made, not
misleading, and the Company hereby agrees to reimburse such Indemnified Person
for any legal or other expenses reasonably incurred by them in connection with
investigating or defending any such action or claim as such expenses are
incurred; provided, however, that the Company shall not be liable to any such
Indemnified Person in any such case to the extent that any such loss, claim,
damage or liability arises out of or is based upon an untrue statement or
alleged untrue statement or omission or alleged omission made in such Demand
Registration Statement or prospectus, or amendment or supplement, in reliance
upon and in conformity with written

C-6

 

information furnished to the Company by such Indemnified Person expressly
for use therein; provided, further, however, that the Company shall not be
liable to any indemnified party in any such case to the extent that such loss,
damage, expense, liability or claim (i) arises from an offer or sale by such
Notice Holder of Registrable Securities occurring during a Suspension Period,
if the indemnified party is a Notice Holder that received from the Company a
notice of commencement of any Suspension Period prior to the making of such
offer or sale or (2) the Holder fails to deliver at or prior to written
confirmation of sale, the most recent prospectus, as amended or supplemented,
and such prospectus, as amended or supplemented, would have corrected such
untrue statement or omission or alleged untrue statement or omission of a
material fact and the Company had previously provided to such Notice Holder
such most recent prospectus, as amended or supplemented, in a timely manner and
in requisite quantities so as to timely permit such delivery by the Notice
Holder.

          (b) Each Notice Holder named as a selling securityholder in any Demand
Registration Statement agrees, as a consequence of the inclusion of any of such
Notice Holder’s Registrable Securities in such Demand Registration Statement,
and each underwriter, selling agent or other securities professional, if any,
which facilitates the disposition of Registrable Securities shall agree, as a
consequence of facilitating such disposition of Registrable Securities,
severally and not jointly, to (i) indemnify and hold harmless the Company, its
directors, officers who sign any Demand Registration Statement and each person,
if any, who controls the Company within the meaning of Section 15 of the
Securities Act or Section 20 of the Exchange Act, against any losses, claims,
damages or liabilities to which the Company or such other persons may become
subject, under the Securities Act, the Exchange Act or otherwise, insofar as
such losses, claims, damages, expenses or liabilities (or actions in respect
thereof) arise out of or are based upon an untrue statement or alleged untrue
statement of a material fact contained in such Demand Registration Statement or
prospectus, or any amendment or supplement, or arise out of or are based upon
any omission or alleged omission to state therein a material fact required to
be stated therein or necessary to make the statements therein, in the light of
the circumstances under which they were made, not misleading, in each case to
the extent, but only to the extent, that such untrue statement or alleged
untrue statement or omission or alleged omission was made in reliance upon and
in conformity with written information furnished to the Company by such Notice
Holder, underwriter, selling agent or other securities professional expressly
for use therein, and (ii) reimburse the Company for any legal or other expenses
reasonably incurred by the Company in connection with investigating or
defending any such action or claim as such expenses are incurred.

          (c) Promptly after receipt by an indemnified party under subsection (a) or
(b) above of notice of the commencement of any action, such indemnified party
shall, if a claim in respect thereof is to be made against an indemnifying
party under this Section 2.4, notify such indemnifying party in writing of the
commencement thereof; but the omission so to notify the indemnifying party
shall not relieve it from any liability which it may have to any indemnified
party otherwise than under the indemnification provisions of or contemplated by
subsection (a) or (b) above. In case any such action shall be brought against
any indemnified party and it shall notify an indemnifying party of the
commencement thereof, such indemnifying party shall assume the defense thereof,
with counsel reasonably satisfactory to such indemnified party (who shall not,
except with the consent of the indemnified party, be counsel to the
indemnifying party), including the payment of all fees and expenses. Such
indemnified party shall have the

C-7

 

right to employ its own counsel in any such case, but the fees and
expenses of such counsel shall be at the expense of such indemnified party
unless the employment of such counsel shall have been authorized in writing by
such indemnifying party in connection with the defense of such proceeding or
such indemnifying party shall not have employed counsel to have charge of the
defense that is reasonably satisfactory to the indemnified party of such
proceeding within 60 days of the receipt of notice thereof or such indemnified
party shall have reasonably concluded upon written advice of counsel that there
may be defenses available to it that are different from, additional to, or in
conflict with those available to such indemnifying party (in which case such
indemnifying party shall not have the right to direct that portion of the
defense of such proceeding on behalf of such indemnified party, but such
indemnifying party may employ counsel and participate in the defense thereof
but the fees and expenses of such counsel shall be at the expense of such
indemnifying party), in any of which events such reasonable fees and expenses
shall be borne by such indemnifying party and paid as incurred (it being
understood, however, that such indemnifying party shall not be liable for the
expenses of more than one separate counsel in any one proceeding or series of
related proceedings together with reasonably necessary local counsel
representing the indemnified parties who are parties to such proceeding). An
indemnifying party shall not be liable for any settlement or compromise of any
such proceeding effected without its written consent, but if settled or
compromised with the written consent of such indemnifying party, such
indemnifying party agrees to indemnify and hold harmless an indemnified party
from and against any loss or liability by reason of such settlement. An
indemnifying party shall not, without the prior written consent of any
indemnified party, effect any settlement of any pending or threatened
proceeding in respect of which such indemnified party is or could have been a
party and indemnity could have been sought hereunder by such indemnified party,
unless such settlement includes an unconditional release of such indemnified
party from all liability on claims that are the subject matter of such
proceeding and does not include an admission of fault, culpability or a failure
to act, by or on behalf of such indemnified party.

          (d) If the indemnification provided for in this Section 2.4 is unavailable
to an indemnified party under subsection (a) or (b) above in respect of any
losses, claims, damages, expenses or liabilities (or actions in respect
thereof) referred to therein, then each indemnifying party shall contribute to
the amount paid or payable by such indemnified party as a result of such
losses, claims, damages, expenses or liabilities (or actions in respect
thereof) in such proportion as is appropriate to reflect the relative fault of
the indemnifying party and the indemnified party in connection with the
statements or omissions which resulted in such losses, claims, damages,
expenses or liabilities (or actions in respect thereof), as well as any other
relevant equitable considerations. The relative fault of such indemnifying
party and indemnified party shall be determined by reference to, among other
things, whether the untrue or alleged untrue statement of a material fact or
omission or alleged omission to state a material fact relates to information
supplied by such indemnifying party or by such indemnified party, and the
parties’ relative intent, knowledge, access to information and opportunity to
correct or prevent such statement or omission. The relative benefit to such
indemnifying party and indemnified party shall be determined in such proportion
as is appropriate to reflect the benefits received by the Company on the one
hand and the Notice Holders on the other hand from the offering of the
Registrable Securities. The parties hereto agree that it would not be just and
equitable if contribution pursuant to this Section 2.4(d) were determined by
pro rata allocation (even if the Notice Holders or any underwriters, selling
agents or other securities professionals or all of them were treated as

C-8

 

one entity for such purpose) or by any other method of allocation which
does not take account of the equitable considerations referred to in this
Section 2.4(d). The amount paid or payable by an indemnified party as a result
of the losses, claims, damages, expenses or liabilities (or actions in respect
thereof) referred to above shall be deemed to include any legal or other fees
reasonably incurred by such indemnified party in connection with investigating
or defending any such action or claim. No person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act)
shall be entitled to contribution from any person who was not guilty of such
fraudulent misrepresentation. The obligations of the Notice Holders and any
underwriters, selling agents or other securities professionals in this Section
2.4(d) to contribute shall be several in proportion to the percentage of
principal amount of Registrable Securities registered or underwritten, as the
case may be, by them and not joint.

          (e) The agreements contained in this Section 2.4 shall survive the
transfer of the Registered Securities by the Holders and sale of all the
Registrable Securities pursuant to any Demand Registration Statement and shall
remain in full force and effect, regardless of any investigation made by or on
behalf of the Holders or such director, officer or participating or controlling
Person.

     2.5 Information by the Holder. The Holder shall furnish to the Company
such information regarding it in the distribution of Registrable Securities
proposed by such Holder as the Company may reasonably request in writing and as
shall be required in connection with any registration, qualification or
compliance referred to in this Article 2.

ARTICLE 3

MISCELLANEOUS

     3.1 Amendment. The provisions of this Exhibit C may not be amended,
modified or supplemented except (a) by an instrument in writing signed by, or
on behalf of, the Company and each Investor or (b) by a waiver in accordance
with Section 3.3.

     3.2 Waiver. No provision of this Exhibit C may be waived except as set
forth in an instrument in writing signed by the party to be bound thereby. Any
waiver of any term or condition shall not be construed as a waiver of any
subsequent breach or a subsequent waiver of the same term or condition, or a
waiver of any other term or condition, of this Exhibit C. The failure of any
party to assert any of its rights hereunder shall not constitute a waiver of
any such rights.

     3.3 Assignment of Registration Rights. The registration rights set forth
in this Exhibit C may be transferred or assigned by an Investor to purchasers
of the Preferred Stock or the Registrable Securities; provided that such
purchasers of the Preferred Stock or Registrable Securities, as the case may
be, agree in writing (i) to be subject to the transfer restrictions applicable
to the Preferred Stock and shares of Common Stock issuable upon conversion
thereof, as set forth in the Purchase Agreement, and (ii) to otherwise comply
with the provisions of this Exhibit C.

     3.4 Severability. Solely in respect of this Exhibit C
and not in respect of the provisions within the Purchase Agreement, in the
event that any provision of this Exhibit C or

C-9

 

the application thereof, becomes or is declared by a court of competent
jurisdiction to be illegal, void or unenforceable, the remainder of this
Exhibit C will continue in full force and effect and the application of such
provision to other Persons or circumstances will be interpreted so as
reasonably to effect the intent of the parties hereto. The parties further
agree to replace such void or unenforceable provision of this Exhibit C with a
valid and enforceable provision that will achieve, to the greatest extent
possible, the economic, business and other purposes of such void or
unenforceable provision.

     3.6 Specific Performance. The parties hereto agree that irreparable
damage would occur in the event any provision of this Exhibit C was not
performed in accordance with the terms hereof and that the parties shall be
entitled to specific performance of the terms hereof, in addition to any other
remedy at law or equity, without the necessity of demonstrating the inadequacy
of money damages.

C-10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}]]